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ABSTRACT 
FUNCTIONALIZED NANOPARTICLES FOR 
AMF-INDUCED GENE AND DRUG DELIVERY 
12th November, 2011 
SOUVIK BISW AS 
The properties and broad applications of nano-magnetic colloids have 
generated much interest in recent years. Specially, Fe304 nanoparticles have attracted 
a great deal of attention since their magnetic properties can be used for hyperthermia 
treatment or drug targeting. For example, enhanced levels of intracellular gene 
delivery can be achieved using Fe304 nano-vectors in the presence of an external 
magnetic field, a process known as 'magnetofection'. The low cytotoxicity, tunable 
particle size, ease of surface functionalization, and ability to generate thermal energy 
using an external alternating magnetic field (AMF) are properties have propelled 
Fe304 research to the forefront ofnanoparticle research. 
The strategy of nanoparticle-mediated, AMF-induced heat generation has 
been used to effect intracellular hyperthermia. One application of this 'magnetic 
hyperthermia' is heat activated local delivery of a therapeutic effector (e.g.; drug or 
polynucleotide). This thesis describes the development of a magnetic nano-vector for 
AMF-induced, heat-activated pDNA and small molecule delivery. 
VB 
The use of heat-inducible vectors, such as heat shock protein (hsp) genes, is a 
promising mode of gene therapy that would restrict gene expression to a local region 
by focusing a heat stimulus only at a target region. We thus aimed to design an Fe304 
nanoparticle-mediated gene transfer vehicle for AMF-induced localized gene 
expression. We opted to use 'click' oximation techniques to assemble the magnetic 
gene transfer vector. Chapter 2 describes the synthesis, characterization, and 
transfection studies of the oxime ether lipid-based nano-magnetic vectors MLP and 
dMLP. The synthesis and characterization of a novel series of quaternary 
ammonium aminooxy reagents (2.1-2.4) is described. These cationic aminooxy 
compounds were loaded onto nanoparticles for ligation with carbonyl groups and also 
to impart a net positive charge on the nanoparticle surface. Our studies indicated that 
the non-toxic magnetoplexes (magnetic nanoparticle + pDNA complex) derived from 
dMLP deliver pDNA into mammalian cells even without external magnetic 
assistance. To date, dMLP is the only polymer-free magnetic gene delivery system 
that can deliver pDNA without any magnetic assistance. 
Chapter 3 of this thesis outlines the synthesis and characterization of other 
oxime ether lipids and details studies using derived-lipoplexes. These lipids were 
evaluated in pDNA and siRNA transfection studies in various mammalian cell lines. 
This work constitutes the first use of an oxime ether as the linking domain in cationic 
transfection lipids. These biocompatible oxime ether lipids can be readily assembled 
by click chemistry through ligation of hydrophobic aldehydes with quaternary 
ammonium aminooxy salts. Our studies showed that the oxime ether lipids 
Vlll 
transfected pDNA and siRNA efficiently in MCF -7, H 1792, and in PAR C 10 cells 
comparable to and in some cases better than commercial transfection lipids. 
Chapter 4 describes the design and characterization of a nano-magnetic 
delivery system for AMF-induced drug (doxorubicin) release. In efforts to develop a 
magnetic formulation free from thermo sensitive materials, such as hydrogels, we 
synthesized three nanoparticle-based doxorubicin formulations using charge 
interactions as the key associative force. To do so, we synthesized and characterized 
a novel cationic oxime ether conjugate at C-13 of doxorubicin. Our investigation 
indicated that the positive charge of the oxime ether drug conjugate tended to bind 
better to the negatively charged nanoparticle than did the other formulations prepared 
in stepwise manner. Our findings show that the nano-magnetic formulations 
remained essestially inactive at body temperature (37.5 °C) and released a majority of 
the cargo only when exposed to an external AMF. Our designed magnetic drug 
delivery platform is the first example of an AMF-inducible system that does not 
depend on the inclusion of thermo sensitive materials. 
Finally, we have developed a bioanalytical application of the highly 
chemoselective oximation chemistry using aminooxy reagent 2.1. Chapter 5 
describes a silica microchip containing micropillars coated with cationic aminooxy 
reagent 2.1. The microchip captures gaseous ketones and aldehydes from exhaled 
human breath. A brief description of microchip fabricated breath analyzer and breath 
analysis is described in Chapter 5. Our studies showed that the acetone capture 
efficiency of the aminooxy-Ioaded microchip was 98%. 
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1.1 Introduction 
The recent and widespread development of nanoscale technologies is 
beginning to change the foundations of disease diagnosis, treatment, and prevention. 
These technological innovations can be grouped into a new field known as 
nanomedicine, and this field can be defined as an offshoot of nanotechnology 
featuring highly specific medical interventions at the molecular scale for curing 
disease or repairing damaged tissues, such as bone, muscle, or nerve" (National 
Institute of Health, Bethesda, MD).l Nanomedicine thus covers a large 
interdisciplinary scientific research area. This includes nanoparticles that have been 
engineered as bio-mimics (e.g., functionalized carbon nanotubes), nanomachines 
(e.g., those made from interchangeable DNA parts and DNA scaffolds), 
nanoconstructs as biomaterials (e.g., nanofibers of peptides and peptide amphiphiles 
for tissue engineering), and nanoscale microfabrication-based devices (e.g., silicon 
microchips for drug release and disease analysis).2 Furthermore, there is a huge array 
of intriguing nanoparticulate-based platforms that is capable of delivering genetic 
materials (pDNA, siRNA), drugs, or diagnostic agents to the desired site of therapy. 
Among these nano-entities, inorganic nanoparticle-based delivery systems have 
emerged as an attractive field of research in recent years. Inorganic nanoparticles 
have two key advantages as a delivery system: ease of preparation with defined size, 
and they can serve as multifunctional carriers by attaching, for example, both reactive 
and contrast elements.3 
Inorganic nanomaterials generally include gold nanoparticles, magnetic 
nanoparticles (mainly Fe304 and yFe203), silica nanoparticles and various quantum 
2 
dots (QD). Magnetic iron oxide nanoparticles, especially magnetite or Fe304 and 
maghemite or y-Fe203 (y-phase defined by a cubic crystal structure) show great 
potential in biomedical research. In addition to being non-toxic,4, 5 flexibly 
functionalized and colloidally stable under physiological conditions, iron oxide 
nanoparticles can be magnetized at the nanoscale range by an external magnetic field. 
This facilitates their purification and also assists in magnetic targeting of the carriers 
to the desired site of therapy.6 These properties make iron oxide nanoparticle 
formulations promising candidates for gene and drug delivery applications. 
Magnetic nanoparticles generate thermal energy when induced with an 
alternating magnetic field (AMF) through the magnetic oscillation of their magnetic 
moments. This is due to what is known as Neel and Brownian relaxation (detailed 
discussion in section IC). The heat generated in this manner has been effectively 
used for non-invasive, hyperthermia-based tumor therapy? Iron oxide nanoparticles 
also can be used as Tr weighted8 magnetic resonance imaging contrast agents. In fact, 
the commercial formulation Feridex I.V.TM was approved for used as an MRI contrast 
agent in humans. However, for unknown reasons this formulation was been 
discontinued by the manufacturer (AMAG Pharmaceuticals, Lexington, MA) after 
November 2008. Combidex™ (Advanced Magnetics, Inc., MA) is another iron oxide 
nanoparticle-based formulation used as an MRI contrast agent. Combidex™ is now 
in Phase III clinical trials.9 The hyperthermic effects and the Trweighted magnetic 
resonance imaging make iron oxide nanoparticles an ideal candidate for theranostic 
(therapeutic + diagnostic) applications. 
3 
This dissertation will describe the present status of magnetic nanoparticle-
mediated gene and drug delivery and my efforts to improve the efficiencies of these 
methods. Specially, my thesis research is aimed at developing an efficient magnetic 
nanoparticle-mediated drug delivery system that can release its cargo in response to 
the heat generated by an externally applied AMF stimulus. 
1.2. Magnetic Vectors for Polynucleotide Delivery 
Gene Therapy 
According to the American Society of Gene Therapy, gene therapy can be 
defined as the "use of genetic material to modify a patient's cells for the treatment of 
an inherited or acquired disease." The therapy involves the introduction and uptake of 
exogenous genetic material into a cell, with incorporation and expression of the gene 
(i.e., transgene) in the nucleus to provide a desired therapeutic effect. For acquired 
diseases like cancer, gene therapy uses genes to directly or indirectly cause the 
demise of the cancerous cells. Various therapeutic effects have been realized with the 
delivery of genes capable of inducing apoptosis, immunogenic responses against the 
host cell, or inactivating oncogenes. 
Despite the original promise, gene therapy remains very inefficient. This 
inefficiency of transfection (i.e., combined output of gene transfer and expression) is 
directly related to the pathway via which DNA makes the journey from delivery to 
nuclear translocation. This mechanism is well studied. 10, 11 The ultimate fate of 
exogenous DNA depends on the ability to overcome the barriers during the transgene 
delivery, and these barriers include: (1) stability in the extracellular space, association 
4 
with plasma membrane, and importantly cellular internalization via endocytosis, (2) 
intra-cellular trafficking including endosomal release, (3) cytosolic diffusion, and (4) 
nuclear localization (Figure 1.1). The driving force behind much gene therapy 
research is to overcome these barriers. In comparison to most small molecule drugs, 
nucleic acids have poor bioavailabilty due to the chemical composition of cell 
membranes, which have a net anionic surface potential. 12 The anionic ribophosphate 
backbone of DNA is electrostatically repulsed from the cellular surface. In addition, 
the immune system may react to exogenous DNA or RNA, which will cause rapid 
enzymatic degradation of the polynucleotide. Therefore, for most gene therapy 
applications, DNA must be delivered to the cell surface in a system that promotes 
cellular internalization while also protecting the DNA from degradation. The ideal 
vector must be able to condense DNA into discrete particles that protect the transgene 
from degradation and provide sufficient delivery into the target cell and its nucleus. 
The vector must be nontoxic, non-immunogenic and should be easy and inexpensive 
to produce. Presently there are three modes of gene delivery: uncomplexed 
DNA/siRNA delivery or "naked" polynucleotide delivery, viral-mediated gene 
delivery, and non-viral mediated gene delivery. 
5 






Figure 1.1. Barriers to effective gene transfer: after aSSOcIatIOn with cellular 
membrane, (1) endocytosis, (2) intracellular trafficking and endosomal escape, (3) 
cytosolic diffusion and (4) translocation to the nucleus and access into the nucleus. 
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Naked DNA (or siRNA) delivery 
The simplest gene delivery strategy is injection/inhalation of 'naked' 
(uncomplexed) nucleic acids (e.g. pDNA, siRNA). This method has attracted 
researchers due to its simplicity and lack of toxicity observed for naked pDNA. 
Several pre-clinical and clinical trials have shown that this strategy is useful for 
delivery of pDNA into skin, muscle, liver, lungs and into some solid tumors. 13, 14, 15 
However, the direct injection of naked nucleic acids into tissue or blood is ineffective 
and limited to a few tissues due to following reasons: first, nucleic acids generally 
undergo rapid enzymatic degradation by nucleases in vivo. Secondly, naked nucleic 
acids cannot reach many organs by systemic injection because the liver rapidly 
sequesters them. Due to its relatively smaller size, kidneys clear siRNA rapidly. 
Finally, the net negative charge of a cellular membrane may repel oligonucleotides or 
pDNA and cause low efficiency of cellular uptake. To overcome these limitations, it 
is necessary to develop gene delivery vectors to safely transport DNA/RNA into 
targeted cells. 
Viral vectors 
Although my thesis research is focused on developing non-viral gene delivery 
vectors, a brief discussion on viral-based gene delivery systems is necessary to 
provide a better perspective of the field. Viruses are nature's most effective 
candidates to infect cells with genetic material. Once the immunological component 
of a virus is dismantled, the viral machinery may be exploited. Likewise, removing 
replication factors from the virus avoids the potential side effects due to non-targeted 
7 
distribution of the viral-vectors. Manipulation of viruses and engineering viral 
vectors have become maj or branch of gene therapy. 16 
Retrovirus vectors (RV) are one of the most effective means for gene transfer. 
Nusbaum et al. in 2000 demonstrated for the first time the proof of concept of 
retroviral gene therapy by treating a genetic disease. 17 Adenovirus is also commonly 
used for viral transduction and it is capable of infecting both dividing and quiescenet 
cells. 18 Although viral vectors for gene transfer fulfill the requirement of efficient 
gene transfer, virus mediated transduction suffers from drawbacks, such as like strong 
immune responses,19 nonspecific transduction,20 limited polynucleotide carrying 
capacity and high cost of production.2I , 22 
Non-viral gene delivery 
Non-viral gene delivery utilizes synthetic carriers to mimic viral transfection 
without the associated side effects. Commonly used non-viral vectors are cationic 
lipids (CL), polymers, and various inorganic nanomaterials. Generally, non-viral 
gene delivery vectors possess positive charge density on their surface to facilitate 
binding to the negatively charged phosphates of the polynucleotide backbone (i.e., 
electrostatic attractions) to form a complex (Figure 1.2). The cationic liposome-
polynucleotide complex is known as a lipoplex and the polymeric counterpart is 
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Figure 1.2. Cationic gene delivery systems: formulation of cationic lipid- and 
polymer-based delivery systems. 
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The advantages of low immunogenicity, the ability to transfect RNA or DNA 
of nearly unlimited size,23, 24 and the relative ease of lipoplex (cationic lipid-plasmid 
DNAIRNA complex) formulation continue to attract interest aimed at developing 
safer and more efficient cationic lipids. Typically a cationic lipid, like 1,2-di-O-
octadecenyl-3-trimethylammonium propane (DOTMA)25 and N-[1-(2,3-
dioleoyloxy)propyl]-N,N,N,-trimthylammonium chloride (DOTAPi6 has a positively 
charged head group for DNA/RNA binding connected to a dual chain hydrophobic 
















Figure 1.3. Chemical structure of DOTMA and DOTAP. 
neutral lipid or co-lipid, such as 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (or 
DOPE), to form a cationic liposome (Figure 1.2). The liposome then condenses the 
DNA/RNA spontaneously to form a lipoplex (Figure 1.2). The lipid bilayer prevents 
the DNA/RNA from degradation by extracellular nuclease. Co-lipids can enhance 
endosomal escape of DNA during transfection.27 The polynucleotide to CL ratio for 
lipoplex formulation must be separately optimized, but generally the lipoplexes are 
formulated with an excess positive charge to provide better interaction with the cell 
10 
membrane. 
Cationic polymer-based gene delivery vectors are also becoming very 
promising in nonviral gene therapy research. Cationic polymers, e.g., poly-L-Iysine 
(PLL),28 polyethylenimine (PEl), 29 polyamidoamine dendrimers (PMAM), 30 and 
chitosan31 can bind with the polynucleotide backbone to form a polymer/DNA or 
siRNA complex or a polyplex (Figure 1.2). In contrast to other polymers, PEl does 
not require an endosomolytic agent due to its intrinsic endosomolytic property. This 
ability to facilitate endosomal escape makes PEl superior to other transfection active 
agents. The PEl backbone consists of repeating '-CH2CH2NH-' ethylenimine motifs 
that provide excellent solubility. Roughly 20% of the nitrogens are protonated at 
physiological pH.32 PEl forms a dense polyplex.33 Due to its "proton sponge" effect, 
polyplexes derived from PEl avoid lysosomal trafficking and enzymatic 
degradation,34 and this usually results in better transfection than other polymers. 
Although PEl is one of the best polymers for gene transfer, in vivo applications using 
PEl suffer from toxicity. The high positive charge density of PEl disrupts the cellular 
membrane.35 Thus, complications arising from vector toxicity affect many PEl-based 
gene therapy approaches.36 
Inorganic nanoparticle-based vectors for gene delivery 
Inorganic nanoparticles are becoming very popular due to their 
biocompatibility, simple method of synthesis, size controllability and ease of surface 
functionalization for various biomedical applications. Inorganic nanoparticles can be 
coated with biocompatible polymers, and linkers can be attached to their surface to 
tether various entities (e.g., targeting elements) for different applications. A 
11 
hydrophobic drug can be attached to these nanoparticles for delivery purpose and 
simultaneous cell specific targeting can be achieved when these drug-loaded nano-
carriers conjugated to a targeting moiety (e.g., peptides or antibodies, Figure 1.4). 
Nanoparticles can behave like a multifunctional platform for theranostics when the 
surface of the particle is further conjugated to a radionucleotide tracer for positron 
emission tomography (PET imaging) or when linked to a fluorescent-active molecule 
for bioimaging. The magnetic nano core makes the nanoparticles MRI active. 
Therapeutic agents, like hydrophilic drugs or nucleic acids, can also be encapsulated 
into the hydrophilic coating shell (Figure 1.4). 
For gene delivery purposes nucleic acids are mostly loaded onto gold 
nanoparticles (GNP) through thiol linkages or electrostatic interaction with cationic 
gold nanoparticles.37, 38, 39,40 Elbakry et al. first developed the PEIIsiRNAIPEIAuNP 
system to deliver siRNA into cells and knock down the expression of a target gene 
based on the self-assembly layer-by-Iayer technology.36 Due to its high transfection 
capacity, PEl coated mesoporous silica nanoparticles (PEI-MSNP) are very common 
vectors for nucleic acid delivery to mammalian cells.41, 42, 43 In addition to their ability 
to increase the plasmid concentration at the cell surface via sedimentation,44 the 
mesopore structures provide the possibility to carry additional elements such as 
drugs,45 magnetic tags,39 and chromophores (to monitor drug delivery or the 
intracellular trafficking of nanoparticles).46 Simple DNA coated calcium phosphate 
nanoparticles (CaP),47, 48 bisphosphonate stabilized CaP49 and cationic lipid coated 
CaPs50 have been used for cellular delivery of exogenous DNA. Ca2+ ion plays an 
important role in boosting transfection activity for these systems. Also, the Ca2+ 
12 
presumably promotes endosomal escape, increases cytosolic stability, and enhances 
nuclear uptake of the DNA.51 However, CaP-based gene carriers suffer from poor 
reproducibility of transfection activity. Stabilizing CaP carriers with lipids is 
currently underway to solve this issue.47 Recent studies have reported that carbon 
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Figure 1.4. Example of multifunctional nanoparticles for theranostic applications. 
disease sites. Most recently AI-Jamal el al. demonstrated delivery of siRNA in vivo 
to central nervous system by using ammonium salt functionalized CNTs.52 
13 
Magnetic nanoparticles for gene transfer 
Mah' s group first demonstrated external magnet-assisted enhancement of viral 
transduction using magnetic nanoparticles.53 Nucleic acid delivery assisted by an 
external magnetic field is now commonly known as magnetofection (Figure 1.5).54 
Although oxide nanoparticles, like CoFe20 4, NiFe204, and MnFe20 4 exhibit superior 
magnetic properties, their use in biomedical applications is challenged by the toxicity 













due to sedimentation 
effcets 
Figure 1.5. Magnetofection: External magnetic field assisted transfection. 
y-Fe20 3 (maghernite), are relatively safe and have been used in humans use as MRI 
contrast agents (Feridex I.V.). Many research groups, such as Lee et al.54 have 
modified the surface to increase the transfection efficacy and reduce the cytotoxicity. 
To achieve enhanced transfection activity with minimized toxicity, investigators used 
various surface adjuvants, such as anionic surfactants (oleic acid),s6 polymers (PEG, 
poly-L-Iysine, dendrimers),57, 58, 59 carbohydrates (chitosan),6o silica particles 
(MCM48),61 proteins (serum alburnin),53, 62 phospholipids,63 cationic cell penetrating 
14 
peptide (TAT peptide),64 transfection reagents (lipofectamine 2000),65 and even 
viruses. 50, 51,66 These surface modifiers prevent agglomeration and add functionality 
that may be further used to conjugate other polymers, such as PEL Most of the 
researchers employ PEl or a modified PEl coating technology to impart a positive 
charge density to the magnetic nanoparticles.63, 67, 68 Huth et al. reported that the 
mechanism of magnetofection usng a PEl -based magnetic vectors, followed 
essentially the same endocytosis process as the related PEl-based polyplexes. 
Release of the genetic material also occurred in similar manner via the "proton 
sponge" effect. 69 The same group also reported that the accelerated nucleic acid 
sedimentation when using the magnetic nanoparticles is the chief force behind the 
success of magnetofection.66 The most noted and recent magnetic nanoparticle 
mediated gene delivery literature is summarized in Table 1.1 (adopted from 
Reference 65). Although magnetic assistance enhances DNA/siRNA transfection 
activity many fold, the transfection activity of these magnetic vectors suffers severely 
when the magnetic field is absent. This is likely to be problematic for gene transfer in 
vivo. Li et al. 55 very recently reported successful delivery of pDNA to a lung tumor 
model in mice without magnetic assistance using a PLL-coated magnetic vector. A 
second major concern of these PEl coated magnetic carriers is their cytotoxocity, 
which is associated with the toxic effects of PEL 
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Year Magnetic Modifying agent Cells/tissue Magnetic Reference 
nanoparticles assistance 
2011 Fe304 PEI, streptayidin NIH3T3, Yes 63 
HeLa 
2011 Fe30 4 Poly(propyleneimine) Saos-2 Yes 56 
dendrimers osteoblasts 
2010 PolymagO Tat peptide U251 Yes 61 
2010 Fe30 4 Silica NCI-H292 Yes 58 
2009 Fe30 4 Oleic acid, HSC-45 Yes 60 
phospholipids 
2009 Fe30 4 Poly-L-Iysine Lung tissue No 55 
Table 1.1. Most recent and noted magnetic nanoparticle mediated gene delivery 
literature (adopted from reference 65). Q. Commercial PEl-coated iron oxide 
nanoparticles (Oz Biosciences, France). 
Chapter 2 of this thesis is focused on designing a PEl-free nano-magnetic 
vector that can transfer pDNA into host cells without external magnetic force. 
Ultimately, we aimed to achieve an AMF-stimulated, heat-induced transgene 
expression using a magnetoplex (magnetic nanoparticleeDNA complex) containing 
heat a shock protein (hsp) pDNA, which will be discussed in Chapter 2 of this thesis. 
To accomplish our goal, we hypothesized using "click" oximation techniques to coat 
the iron oxide nanoparticle surface with cationic moieties that facilitate pDNA 
delivery. 
As a part I of thesis, we aimed to achieve: (a) the design, synthesis and 
characterization of cationic iron oxide nanoparticles for efficient gene delivery, and 
(b) the evaluation of a heat-activated, hsp-promoted gene expression using thermal 
energy generated by a magnetic vector under an external AMF-stimulus. 
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1.3. Magnetic hyperthermia-induced drug delivery 
Magnetic hyperthermia 
According to the National Cancer Institute (Bethesda, MD), hyperthermia 
(Greek for 'overheating') is a type of cancer treatment in which body tissue is 
exposed to high temperatures (up to 45°C). Research has shown that high 
temperatures can damage and kill cancer cells, usually with minimal injury to normal 
tissues.7o By killing cancer cells or damaging proteins and structures within cancer 
cells,7) hyperthermia may shrink tumors. Thermoablation is another form of 
thermotherapy where the temperature range is 46-56 °C. The higher temperature in 
this case leads to direct tumor destruction by cell necrosis and carbonization.72 The 
notion of hyperthermia is as old as anti-cancer medicine itself. Indeed, heat therapy 
was first mentioned as a treatment of breast cancer more than 5000 years ago.73 Since 
hypoxic (poorly oxygenated) cancerous cells are much more resistant to radiation 
therapy than that of euoxic (well oxygenated) cancerous cells, and since hypoxic 
cancerous cells are more heat sensitive than euoxic cells,74 the combination of heat 
and radiation therapy is a promising therapeutic modality.75 
The main sources of thermal energy to induce hyperthermia fall into three 
categories: (a) contact with externally heated liquids, (b) contactless applicator (e.g., 
irradiation using ultrasound, microwave, radiofrequencies, or infrared devices) and 
(c) use of an inserted heating source (probes, laser fibers, and mediators).76 Unlike 
other inserted heating sources, mediators convert the electromagnetic energy into heat 
when exposed to an external electric or magnetic field. Macroscopic mediators are 
inserted within the body via surgical procedure, whereas micro- or nano-scaled 
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mediators are injected as particle dispersions. These mediators are heated either by a 
captive applicator, or by applying an inductive applicator to magnetizable particles, 
where the electric component (E-field), which can lead to uncontrollable heating of 
the tissue, is lowered to the benefit of magnetic field (H-field) to generate heat 
energy.77 Inductive mediators seem to be more useful because cells do not contain 
any intrinsic magnetic materials that could generate uncontrolled heat in an 
alternating magnetic field. For patient comfort, the frequency of an alternating 
magnetic field (AMF)-induced hyperthermia should be higher than 50 kHz to avoid 
neuromuscular stimulation and less than 10 MHz for the appropriate penetration 
depth of the frequency-field. 78 Surgically inserted ferromagnetic rods have been 
placed into tumors to serve as interstitial macroscopic mediators.79 The basic 
limitations of this technique are stressful surgical interventions, lack of accessibility 
to tumors, potential migration of the rods, and non-uniform temperature patterns. 
The most recent magnetic hyperthermia models are based on micro- or nano-
sized mediators in the form of an injectable colloidal dispersion of magnetic particles. 
Magnetic nanoparticle-mediated heating occurs via two main mechanisms: (a) 
external AC magnetic field supplies energy and assists magnetic moment rotation by 
overcoming the energy barrier (E = KV; K is the anisotropy constant, and V is 
volume of the magnetic core) so that energy is dissipated when the particle moment 
relaxes to an equilibrium orientation, a phenomenon known as Neel relaxation; and 
(b) rotational Brownian motion can also generate heat from magnetic nanoparticles 
within a carrier liquid due to the torque generated on the magnetic moment by an 
AMF.73 The prerequisite criterion for clinical application is nontoxicity of the 
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magnetic nanoparticles. To date, magnetite (Fe304) and maghemite (y-Fe203) 
nanoparticles with satisfactory biocompatibility have been under intensive 
investigation. Gilchrist reported the first application of iron oxide mediated 
hyperthermia in vivo in 1957. The first Phase I clinical trial of magnetic 
hyperthermia was done by MagForce Nanotechnology Co. (Berlin, Germany) in 2005 
with 14 patients suffering from glioblastoma. In this trial, the feasibility of magnetic 
Figure 1.6. AMF applicator for humans: NanoActivator™, MagForce 
Nanotechnologies AG, Berlin. A fiber-optic thermometry unit is part of the 
applicator. Image was taken from Magforce website. 
hyperthermia as a therapy was evaluated usmg a 100 kHz AMF applicator 
(NanoActivator™, MagForce, Germany, Figure 1.6) and amino silane-coated iron 
oxide nanoparticles (NanoTherm™, MagForce). 80 Hyperthermia was well tolerated 
with radiation and with minor or little side effects. Signs of local tumor control were 
observed.6 The Phase II trail of this study is in progress with 65 patients.81 In fact, 
this hyperthermia therapy was cleared for the market in European Union countries 
last year, and has begun the treatment in patients in Germany under "an individual 
19 
patient agreement." Investigators in Japan also have reported the clinical application 
of magnetic hyperthermia for melanoma treatment.82 
In summary, there is exciting evidence that raises the prospect of therapeutic 
application of magnetic-hyperthermia in humans. The continuous effort in building 
proper AMF generators for inducing magnetic hyperthermia in humans, gaining idea 
of biodistribution of these nanoparticles, and acquiring knowledge of magnetic 
nanoparticle toxicity is definitely strengthening the belief that AMF-induced 
magnetic nanoparticle-mediated thermotherapy will be a viable treatment option. 
Magnetic hyperthermia-triggered drug release 
Magnetic hyperthermia opened a new avenue in stimuli-triggered non-
invasive drug delivery technology whereby drugs encapsulated within thermo-
sensitive polymers, gels, or lipids containing magnetic nanoparticles (for generating 
thermal energy to change the conformation of the carrier matrix) could be stimulated 
by exposure to an AMF to cause the release. Once at the target site, a drug is released 
from the carrier upon AMF-induction to create a local high concentration of drug 
resulting reduced side effects. To date, the AMF-triggered or magnetic hyperthermia-
induced drug release platforms rely on two basic principles: magnetic heating (or 
magnetic hyperthermia) of nanoparticle and a thermally responsive or (-rupturable) 
coating. 
Magnetic nanoparticles that are designed with the proper composition and size 
to achieve heating using an AC magnetic field are generally placed inside a 
thermally-responsive matrix. A polymer can also be coated directly onto the 
nanoparticle, or a self-assembled structure (e.g., micelles, liposomes or 
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polymersomes) can be devised to encapsulate the nanoparticles. For biomedical 
applications, the coating must open or partially rupture to release a drug when heated 
above physiological temperatures. There are three mechanisms in which heat energy 
can cause the structural change in matrix to release the drug (Figure 1.7). Generated 
heat can swell the matrix and that can cause the release (Figure 1.7 A). 83 In 
squeezing-controlled release (Figure 1.7B), an already hydrated gel collapses rapidly 
when heated, exuding water and much of the imbedded drug with the water.84, 85 Liu 
et af. 82 encapsulated doxorubicin (Dox, an anti-cancer drug) and iron oxide 
nanoprticles inside of Pluronic F127 (FI27) matrix and demonstrated Dox release by 
AMF induction. Considerable volume shrinkage of F127 matrix due to heat 
generated by magnetic hyperthermia causes the instantaneous release of Dox. This 
system, however, is not suitable for in vivo applications because cargo release occurs 
at 35°C, which is lower than the body temperature (37.5 °C). In another example, 
Chaubey et al. used a naturally occurring genipin cross-linked gelatin nanoparticles 
for encapsulating Fe304 nanoparticles and Dox. Drug release was observed when the 
above system was induced by an AMF and this system is based on swelling 
controlled release.8o Iron oxide nanoparticles and drug encapsulated alginate 
microsphere are also developed for magnetically controlled heat-responsive drug 
release.86, 87 In these cases, nanoparticle-induced thermal energy twists and shakes the 
molecular chains, resulting in an increase of wall permeability that causes increased 
diffusion of the drug (Figure 1. 7C). 84 BrUle et al. 86 observed cytotoxicity of this 
carrier even before AMF-pulse, indicating premature drug release at 37.5 °C. 
Because squeezing-based hydrogel systems would release a drug when heated, they 
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are preferred over swelling-controlled systems for the development of 
magnetothermally-triggered drug delivery systems. However, when a hydrogel is 
placed in an aqueous environment (such as the human body), the gel will swell, 
leaving the mesh open for drug diffusion and release prior to the triggering event, so a 
squeezing-controlled release platform is not ideal for delayed triggering events. Hsu 
et al. encapsulated lipophilic drug tetracaine and y-Fe203 nanoparticles (size 5-25 nm) 
in a solid lipid nanoparticle (SLNP) matrix. Drug release was observed when the 
vehicle was stimulated with a 25 kHz (frequency), 60 kAlm AMF.88 Lipid transition 
change was induced by heat generated from NP heating which caused diffusion of the 
drug from the matrix. The low frequency of the AMF and high temperature rise (37-
50°C in 20 min) may face challenges in in vivo studies. Very recently Thomas et al 
developed a smartly engineered magnetic core (Zn-doped iron oxide nano crystal)-
silica shell nano-system in which the anti cancer drug doxorubicin was entrapped via 
diffusion. The mesopores then were blocked by curcubit[6]uril (a macrocyclic 
aminal) to prevent nonresponsive drug leakage at 37.5 °C.89 The valves opened and 
released the drug efficiently when an AMF-stimulus was applied. 
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A. Thermo-responsive swelling 
AMF 
NP heating triggers 
swelling of the matrix 
Magnetic nanoparticles (NP) 
and drug encapsulated 
in thermo-sensitive matrix 
• Magnetic nanoparticles (NP) 
• Encapsulated cargo 
B. Thermo-responsive squeezing 
AMF 
NP heating triggers 
contraction of the matrix 
C. Thermo-responsive opening of grafts 
AMF 
NP heating triggers 
conformational change 
of the matrix 
.. 







Heat generated from magnetic 
hyperthermia swell the matrix 
to release the cargo 




Heat generated from magnetic 
hyperthermia squeeze the 
matrix to release the cargo 
Heat generated from magnetic 
hyperthermia opens grafts to 
release the cargo 
Figure 1.7. Thermo-sensitive formulations for controlled release of payloads. A. 
swelling, B. squeezing, and C. change in molecular conformation of matrix. 
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To address the challenge of premature cargo release, we aimed to design 
magnetic nano vehicle for AMF-controlled release that does not rely on a 
thermosensitive material. As part II of my thesis, we set out to assemble a simple 
drug-conjugated nano-sized magnetic drug delivery platform using "click" oximation 
chemistry. Our final objective is to demonstrate AMF-induced drug release from our 
custom magnetic vector. Chapter 4 of my thesis will describe the development of 
the first magnetic thermo-sensitive polymer-independent delivery system to address 
the above stated challenges. 
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CHAPTER 2 
AMF-INDUCED hsp-PROMOTED GENE THERAPY 
USING NANO-MAGNETIC VECTORS 
2.1. Introduction 
2.2. Results and Discussion 
2.3. Conclusion and Future Directions 
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2.1. Introduction 
Logically, the control of therapeutic gene expression within tumors would 
enhance the therapeutic impact of gene therapy. Along these lines, inducible plasmid 
promoters to control gene expression would make the spatial and temporal targeting 
of therapy more feasible. 90, 91 One smart strategy for induced gene expression is based 
on chemical signaling. Examples include tetracycline-inducible or -suppressible gene 
expression systems based on bacterial tetracycline operon.92 Disease-specific gene 
activation systems have also been reported for induced gene therapy.93, 94 However, 
two major obstacles of this strategy are: (a) tumor specific promoters must be 
identified for each individual tumor, and (b) the ability to switch off the transgene 
expression on demand is still problematic.95 
Among the various inducible gene expreSSIOn systems, external stimuli-
induced systems have some unique advantages. Chief among them is the ability to 
focus the inducing agent in a spatially targeted region. Such a system has been 
described usmg gamma radiation and the Egr-l promoter.96, 97 Targeting was 
achieved either by radiotherapy or by systemic injection of radioisotopes 
accumulating in the tumor cells. However, radiotherapy has the disadvantage of 
using ionizing radiation. In another approach, thermal energy can be used to trigger 
gene expression in an inducible gene expression system. Among the most commonly 
used heat-inducible promoters are the heat shock protein (hsp) genes, such as the 
hsp70 family. Their transcription is upregulated in response to a toxic insult to the 
cell, perticularly exposure to heat.98 Importantly, the basal expression of genes 
controlled by an hsp70 promoter region is nearly undetectable, whereas heat-induced 
26 
expression is comparable to that observed with the popular cytomegalovirus early 
(CMV) promoter.99 Thus, it is feasible to restrict gene expression to a local region by 
focusing the heat stimulus only on the target region (Figure 2.lA). It has been 
demonstrated that hyperthermia generated heat can be used for non-invasive and non-
toxic alternative regulator for local gene expression using a thermo-inducible 
promoter. tOO One of the main advantages of hyperthermia over radiotherapy is that 
hyperthermia is potentially suitable for diseases other than cancer. There appear to be 
long-term side effects in experimental cancer treatments using hyperthermia, 
particularly in the temperature range that is most effective for heat-induced gene 
induction. Among many examples, Huang et al. 95 have demonstrated that in vitro 
expression of a heterologous gene with a heat shock protein 70 promoter could be 
elevated 500 to lOOO-fold over background by heat generated from a hot water bath 
(39-43 °C). Verkis et al. 101 demonstrated in vitro GFP (green fluorescent protein) 
reported expression using thermo-inducible hsp promoter at 43°C. Duration of 
hyperthermia in this study was 30 min. Moonen et al. used the same heat shock 
promoter and GFP reporter plasmid for heat-induced gene expression using MRI-
guided focused ultra sound technique to generate thermal shock in the tumor tissue. 102 
In another study Smith et al. 103 activated an hsp-promoted luciferase reporter 
construct for heat-induced gene expression using ultrasound-based hyperthermia. 
The main obstacle with hot water bath hyperthermia is to generate enough 
heat energy in tumors located deep within the body. This somewhat invasive therapy 
may also face challenges in in vivo clinical applications. UltrasoUfld-mediated 
hyperthermia suffers with UfIdesirable temperature rise at the muscle-bone interface. 
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An alternative strategy to avoid whole body hot water bath hyperthermia or 
ultrasound-induced hyperthermia for heat inducible gene therapy system is to apply 
magnetic nanoparticle-mediated intracellular AMF-stimulated hyperthermia 
technology to induce localized gene expression (Figure 2.1B). Ito et al. have 
combined TNF-a gene therapy driven by a heat-inducible hsp70 (heat shock protein 
70) promoter with hyperthermia produced by AMP-irradiation of cationic liposome-
iron oxide nanoparticle formulations. \04 Tang et al. also developed a heat-inducible 
gene expression system in which thermal energy generated by PEl coated Mn-Zn 
ferrite magnetic nanoparticles under an alternating magnetic field (AMF) was used to 
activate gene expression. \05 They also used the h~p70 promoter. The NPs in this 
system are challenged with biocompatibility issues due the composition of the Mn-Zn 
and due to the PEl coating. In this experiment, however, authors injected a second 
dose of nanoparticle formulation (2.6 mg or 4.6 mg of magnetic particles) before 
AMF-induction, which might cause aggregation of particles in a particular zone of the 
tumor and might result in non-uniform heating in tumor during clinical applications. 
The successful fusion of PEl-free magnetic nanoparticle-mediated gene 
transfer, AMF-induced intracellular nanoparticle heating and heat-induced apoptotic 
gene expression would constitute a non-invasive, localized treatment of cancer. This 
is our goal at the onset of my thesis research. 
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Thermal energy, hyperthermia, 43 °C 
heat activates hsp promoter 
Heat-stimulated gene expression 
proteins generated by heat: luciferase, 
GFP 




Heat-stimulated gene expression 
AMF-induced NP heating activates hsp promoter luciferase, GFP produced 
magnetoplex 
PEl-coated cationic NPs 
pNDA containing heat shock 
promoter gene 
Figure 2.1. Heat-stimulated hsp-promoted controlled gene expression. A. Thermal 
energy controlled (e.g. , hyperthermia) heat-activated hsp-promoted gene expression. 
B. Noninvasive AMF-induced NP heating triggerd heat-stimulated gene expression. 
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2.2. Results and discussion 
To achieve our goal, we ftrst set out to design a biocompatible PEl-free 
cationic iron oxide (Fe304) nanoparticle (NP) formulation to function as an efftcient 
pDNA delivery vehicles. In keeping with our research theme, we aimed to use 
"click" oximation technology for NP surface manipulations. Chemoselective click 
ligation of an aldehyde or ketone carbonyl group with an aminooxy counterpart to 
form an oxime ether linkage (i.e., oximation, Scheme 2.1A) is a key step in the 
synthesis of numerous bioconjugates. 106, 107, 108 Oxime ether linkages also are used as 
a mechanism for pro-drug generation, 109 and are present in FDA-approved 
pharmaceuticals, such as fluvoxamine. l1O Very recently (May, 2011), Cho et a/. ll1 
published a report in which they conjugated an aminooxy terminated 30 kDa PEG 
linker to human growth hormone using oximation technique. This modifted hormone 
(ARX201) bearing oxime ether linkage was synthesized to achieve a molecular size 
suitable for minimizing renal clearance yet maintaining acceptable viscosity for 
enhanced therapeutic effect. In fact, ARX201 is now in Phase II clinical trials. 
Our ftrst strategy was to pursue the surface modiftcation of commercially 
available dextran-coated NPs (fluidMAG-DX, Chemicell, Berlin, Germany) using an 
oximation approach. We hypothesized that dextran-coated magnetic iron oxide 
nanoparticles (50 nm) could be activated for conjugation to cationic aminooxy 
reagents by cleaving the vicinal diol groups of the carbohydrate domain. Thus, 
periodate oxidation of fluidMAG-DX would generate multiple surface aldehyde sites 
(Scheme 2.1B) for reaction with cationic aminooxy reagents. We planned to condense 
cationic quaternary ammonium aminooxy salts with the aldehyde groups to generate a 
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positive charge density on the NPs for ultimate DNA-binding and for subsequent 
transfection applications. 
A. 
R~ONH2 + 0Y'R' oximation. R~ONY'R' 
B. 
fluidMAG-DX 








+. + + Cationic NP 
Scheme 2.1. A. Chemoselective "click" oximation between aminooxy and the carbonyl 
group of either a ketone or aldehyde. B. Strategy for synthesizing a cationic NP: generate 
aldehyde groups by periodate oxidation, and then react the oxidized NP with a cationic 
aminooxy reagent. 
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To initiate our above stated plan we first synthesized and characterized a panel 
of novel quaternary ammonium aminooxy salts (Figure 2.2, 2.1-2.4) for use in the 
final oximation step.lI2 We adapted Grochowski's methodology to synthesize these 
cationic aminooxy reagents. I 13 The cationic amiooxy reagents can serve as 
nucleophilic reagents to access cationic materials more readily than their electrophilic 
counterpartsl14, 115 because the chemospecifIc oximation reaction between aminooxy 
and aldehydelketones is expected to be facile. Our interest in gene transferl16, 117 and 
the fact that hydroxyethylated polar domains enhance the transfection efficiency led 
us to prepare hydroxyethyl-functionalized analogs 2.3 and 2.4. Consequently, we 







Figure 2.2. Panel of quaternary ammonium aminooxy reagents. 
Synthesis of quaternary aminooxy salts 
Reaction of the commercially available ethanolamines 5 and 6 (Scheme 2.2A) 
with N-hydroxyphthalimide (NHP) under Mitsunobu conditions (equimolar amounts 
of NHP/PPh3IDIAD) furnished phthaloyloxy amines 7.1 and 8.2, respectively. 
Amine quaternization was best accomplished by gently warming the amines in 
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methyl iodide (ca. 0.2 M). The resultant, crude ammonium iodides were treated 
directly with hydrazine in ethanol to cleave the phthaloyl groups. Aminooxy reagents 
2.1 and 2.2 were purified and isolated as filtrate from hot acetonitrile in good overall 
yield. 
Monosilylation of di- (6) and triethanolamine (12) was accomplished by 
reacting an excess of each ethanolamine with TBSCI as the limiting reagent. The 
resultant, mono-protected ethanolamines 9.1 and 13.1 (Scheme 2.2B) were then 
transformed to the corresponding N-(2-hydroxyethyl)-functionalized ammooxy 
reagents (2.3 and 2.4) using the path established for synthesis of reagents 2.1 and 2.2. 
Desilylation of the more polar phthaloyloxy amine 10.1 proceeded smoothly on work-
up by stirring with aq. HCI, this approach did not work for phthaloyloxy amine 14.1. 
In fact, reaction with aqueous HF instead of TBAF ultimately furnished the desired 
final target 2.4. My laboratory colleague, Mr. Xuan Huang, synthesized the reagent 
2.4. 
The IH NMR and l3C NMR clearly indicated that phthaloyl group was 
cleaved during hydrazinolysis process and aminooxy or -ONH2 group was generated. 
IH NMR spectra of phthaloyl protected quaternary ammonium salt and 2.1 are 
included (Figure 2.3). 
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A. 
I a I b, C 
HO~N'R - PhthO~N'R -
















6: R = CH3 
a ~ R' = H 
9.1: R = CH3 
R' =TBS 
-
12: R = CH2CH20H 
a ~ R' = H 
13.1: R = CH2CH20H 
R' =TBS 
N-R 
- 2.4 r (70%) 
R'O 
10.1: R' = TBS 
(not isolated) 
11.2: R' = H (71%) 
14.1: R = CH2CH20Phth 
C ~ R' = TBS (82%) 
15.2: R = CH2CH20Phth 
R' = H (86%) 
Scheme 2.2. Synthesis of cationic aminooxy reagents. Reagents and conditions: A. 
Phth = phthalimidoyl; (a) N-hydroxyphthalimide, PPh3, DIAD, THF, 0 °C - rt, 12 h; 
(b) CH3I, sealed tube, 45°C, 2 h; (c) H2NNH2-H20, EtOH, rt, 12 h. B. TBS = t-
BuMe2Si; (a) TBSCI (0.2 eq), Et3N (l eq), CH2Ch; (b) N-hydroxyphthalimide, PPh3, 
DIAD, THF, 0 °C - rt, 12h; (c) 48% aq. HF, THF, 0 °C - rt, 12h; (d) CH3I, sealed 
tube, 60°C, 2h; (e) H2NNH2-H20, EtOH, rt, 12h. 
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Figure 2.3. IH NMR spectra ofphthaloyl protected salt and 2.1 in DMSO-d6. 
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Preparation of cationic fluidMAG 
We performed NaI04 oxidation on the fluidMAG-DX NPs to form aldehyde 
groups at NP surface (Scheme 2.3).118 Although elemental analysis data of the 
oxidized fluidMAG-DX initially indicated the presence of aldehyde groups at the NP 
surface, inconsistent elemental analysis values also indicated poor reproducibility of 
this step. This raised a concern about the consistency of the quality of the 
commercial fluidMAG-DX. Oximation then was employed to conjugate the cationic 
mono-aminooxy reagent 2.1 to add positive charge density at the NP surface to 
Figure 2.4. SEM micrograph of commercial fluidMAG-DX. 
furnish cationic fluidMAG (CFM, Scheme 2.3). According to elemental analysis 
data, we could succeed to conjugate only ~ 1.0% nitrogen after oximation to the 
CFM, whereas theoretical %N in CFM was approximately 6%. The functionalized 
particles prepared from this strategy never showed encouraging magnetofection or 
transfection activity in studies using breast cancer cells (MCF-7). Lack of nitrogen 
content at the NP surface indicated lack of cationic head group, which is the reason of 
poor transfection activity of the fluidMAG-DX derived formulation. In fact, we 
noticed inconsistent chemical behaviors of the commercial fluidMAG-DX from batch 
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to batch. Size determination using Scanning Electron Microscopy revealed that the 
size of the commercial particles were larger than the vendor's claim (Figure 2.4). 
SEM images of these particles also demonstrated a large size distribution. For these 
reasons, we abounded the strategy of functionalization of commercial material. 
fluidMAG-DX 







Cationic fluid-MAG (CFM) 
excess reagent 2.1 , H:P, 








Cationic surface of the CFM 
Scheme 2.3. Synthesis of cationic NPs. Aldehyde moieties are formed at the surface 
of the fluidMAG-DX NPs by periodate oxidation. Subsequent oximation usmg 
cationic aminooxy reagnet 1 then inputs a net positive charge to the particles. 
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Development of magnetic lipid particles (MLPs) 
Unhappy with the quality of the commercial fluidMAG-DX prepartion, we 
decided to develop our own custom nano-magnetic delivery vector for polynucleotide 
delivery. To initiate our new plan, we first synthesized negatively charged Fe304 
nanoparticles (NP) according to a co-precipitation method described by Mikhaylova 
et al.1l9 Zeta potential measurements revealed the NPs had a surface charge of -32 
mY. X-Ray Diffraction (XRD) and Energy-Dispersive X-Ray Spectroscopy (EDX) 
measurements confirmed Fe304 magnetite and Transmission Electron Microscopy 
(TEM) indicated particles with an average 5-10 nm diameter. 
Without the aid of established transfection lipids and their co-lipid 
formulations, the use of lipid coated nanoparticle vectors for gene transfer remains 
largely unexplored. Our research group's interest in oximation and program on 
developing non-viral gene delivery systems1l6, 120, 121, 122 led us to devise a flexible 
method for stepwise construction of a transfection-active lipid coating directly on the 
surface of iron oxide nanoparticles. Inspired by the nanoparticle 'click' conjugate 
work of Miller I 23 and Mirkin,124 we sought to harness click chemistry to attach lipid 
side chains onto aminooxy functionalized NPs using oximation methodology 
To functionalize the NP surface with an aminooxy layer, the NPs were treated 
with an excess (ca. 3.3 wt. equivalents) of cationic aminooxy reagent 2.2 (Scheme 
2.4). The resultant aminooxy-coated nanoparticles (NP-l) were readily isolated by 
magnet-assisted sedimentation and, using this method repeatedly, were washed 2X to 
remove any unassociated aminooxy compound. Dry weight measurements 
consistently indicated a deposition of2.2 on the surface ofNp·l in the range of 1.27-
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1.30 !-tmol/mg, which is nearly 2X104 aminooxy groups/particle. We hypothesized 
that the close association of 2.2 with the nanoparticles presumably is driven by a 
combination of hydrogen bonding and electrostatic interactions. 125 The relative 
extent of these associative interactions is unclear. The observed reduction in zeta 
potential for NP·l to -16 m V reflected a partial neutralization of surface charge by 








Scheme 2.4. Synthesis ofNp·1 and conjugation ofFITC2 to the Np·1. 
We evaluated the availability of arninooxy groups on Np·l by performing a 
labeling experiment. We used an aldehyde fluorescent probe FITC2 for this study 
(Scheme 2.4). After mixing the particles with FITC2, conjugated were magnetically 
separated and washed 2X with methanol to furnish Np·l·FITC2. FITC2 was mixed 
with only NP in a same way to prepare Np· FITC2 that served as a control. The UV 
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measurements indicated the aldehyde substrate FITC2 is bound to the nanoparticle 
only when compound 2.2 is present (Figure 2.5). FITC2 was not bound unless 
compound 2.2 was loaded onto the NP fIrst, implicating the oxime ether linkage as 
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Figure 2.5. UV-visible spectrum of NP-Ioaded with FITC2, Np·l and NPs. UV-
Visible spectroscopy measurements were taken of NP, NP·1, NP·1·FITC2 and 
FITC2 at concentrations of 0.025 mg NP/mL (water). As a control, unmodifIed NPs 
were reacted with FITC2. 
We were gratified to fInd that reaction ofNp·1 with excess myristaldehyde (7, 
Scheme 2.5A) resulted in smooth attachment of hydrophobic chains via oximation to 
give the corresponding magnetic lipid particles (MLP, Scheme 2.5A). The MLP 
formulation demonstrated a signifIcantly more positive zeta potential than NP·1. 
Weight analyses indicate roughly one equivalent of myristaldehyde is attached during 
the oximation step, suggesting that single chain lipid 8.1, or likely a mixture of lipids 
8.1 and 8 (Figure 2.6A), is bound at the MLP surface and possibly as a surrounding 
bilayer (Figure 2.6B), is most likely reason for the shift in zeta potential (+ 40 m V). 
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Scheme 2.5. Strategies for synthesis of lipid coated nano-magnetic carriers. 
Conditions: Each functionalization step was done in methanol at room temperature 
for 12 h; isolation and purification were performed via magnetic separation. Surface 
charge (s-potential) measured in H20. A. Preparation of magnetic lipid particles 
(MLP) using a stepwise oximation approach. B. Preparation of dMLP via direct 
loading of oxime ether lipid. 
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Evaluation of the transfection efficiency ofMLP in MCF-7 breast cancer cells 













NP surface --------, 
Figure 2.6. A. Cationic oxime ether formed on reaction with meristaldehyde at the 
NP surface. B. Schematic representation of bilayer formation at NP surface. 
(MLP·DNA complex) were prepared at various weight ratios by direct mixing with 
the luciferase pDNA followed by application to cells in the presence of a static 
magnetic field. The data (Figure 2.7) indicated that MLP transfection efficiency is 
roughly equivalent or slightly higher than that of the commercial transfection agent 
Lipofectamine 2000 (positive control) at magnetoplex weight ratios exceeding 120, 
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while activity drops off rapidly at higher ratios. Not unexpectedly, given the negative 
zeta potential of NP·l, magnetoplexes derived from Np·l did not transfect (400-600 
RLUs). 
Unfortunately, as with most magnetic nanopartic1e delivery systems, removal 
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Figure 2.7. Magnetofection of MCF-7 cells using MLP-derived magnetoplexes in 
presence of 10% FBS. Results are expressed as total relative light units (RLU). 
Transfections were performed in 24-well tissue culture plates using 0.025 mg luciferase 
reporter construct (pCMVLuc) per well with 18 h transfection time. Each data point 
reflects the mean value of three separate transfections and the standard deviation from 
the mean. LFT = Lipofectamine 2000. 
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Since additional myristaldehyde could not be attached by further reaction with 
MLP, we probed whether direct attachment of the dual-chain lipid Sll2 to iron oxide 
nanoparticles could be accomplished. Reaction of excess S with the NPs followed by 
our washing protocol delivered dMLP, magnetic lipid particles formed on direct 
exposure to the cationic oxime ether lipid. Lipid loading was measured at 1.25-1.35 
/-tmol/mg. The TEM micrograph of dMLP (Figure 2.8) shows spherical shaped 
nanocrystalline particles around 5-10 nm in diameter. 
Evaluation of dMLP in the transfection of MCF-7 cells (Fig. 2.9) revealed 
notable differences in comparison to transfections using MLP. Under 
magnetofection conditions (Figure 2.9A) and in the presence of serum, dMLP-
magnetoplexes are considerably more active than MLP-magnetoplexes at all 
Figure 2.S. TEM micrograph of dMLP. 
magnetoplex ratios and substantially more efficacious. The optimal dMLP-
magnetoplex-120 exhibits more than three orders of magnitude higher transfection 
activity (ca. 1425-fold) than the transfection standard Lipofectamine 2000. More 
remarkable are the activities of dMLP-magnetoplexes in the absence of a magnet 
(Figure 2.9B). The dMLP-derived magnetoplexes are not dependent on magnet-
assisted sedimentation for their activity, unlike MLP-magnetoplexes. At 
magnetoplex ratios between 90 and 540, the data indicate dMLP significantly 
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promotes transfection relative to the positive control (e.g., magnetoplex-180 exhibits 
>40-fold higher activity than Lipofectamine 2000). We also examined if the 
observed activity of dMLP is due to any unattached lipid 8 acting independently as a 
transfection agent. We examined 8 at various lipid:DNA ratios without any helper 
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Figure 2.9. Magnetofection (A) and transfection (B, no magnet) of MCF-7 cells 
using dMLP-derived magnetoplexes in presence of 10% FBS. The results are 
expressed as total relative light units (RLU). Transfections were performed in 24-
well tissue culture plates using 0.025 mg luciferase reporter construct (pCMVLuc) per 
well with 18 h transfection time. Each data point reflects the mean value of three 
separate transfections. Error bars show the standard deviation from the mean. LFT = 
Lipofectamine 2000. 
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Comparison of the measured zeta potentials for MLP- and dMLP-
magnetoplexes (Figure 2.10) indicates different plasmid-binding properties. The 
dMLP formulations achieved net positive magnetoplexes at lower particle 
concentrations. Furthermore, the use of dMLP results in a fairly uniform 
magnetoplex charge over a wide range of formulation ratios as reflected by the 
consistent transfection activities observed for the dMLP-magnetoplexes, particularly 
in the absence of a magnet, which is in agreement with transfection activities. 
A cell viability assay was performed to evaluate the cytotoxocity of dMLP-
magnetoplexes using alamarBlue kit (Invitrogen Corporation, CA). The cytotoxicity 
study revealed that magnetoplexes derived from dMLP were less toxic towards MCF-
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Figure 2.10. Zeta potential measurements (H20) of MLp· (light bars) and dMLp· 
magnetoplexes (dark bars) at various nanoparticle to pDNA ratios; the concentration 
of NP in the aqueous particle samples was 0.1 mg/mL; magnetoplexes were 

















Blank 30 60 90 120 180 240 360 540 810 DNA LFf 
Formulation 
Figure 2.11. Cell viability study of MCF-7 cells transfected with DNA alone (DNA), 
Lipofectamine 2000 (LFT) and dMLP-magnetoplexes at various dMLP:pDNA ratios. 
At 18 h post transfection, alamarBlue® was added to cells and the fluorescence 
intensity (arbitrary fluorescent units) was measured at the onset (light bar) and then 
measured again at 4 h post addition (dark bar, n = 3). 
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AMF -induced hsp gene-promoted gene expression 
With an efficient route to synthesize positively charged, lipid-coated magnetic 
nanoparticles (dMLP) in hand, and having carefully optimized tansfection conditions 
in vitro, we next sought to develop a heat-inducible gene expression system in which 
the thermal energy generated by dMLP under an AMF -stimulus would be used to 
activate the gene expression. To pursue our goal we first purchased an hsp70-
luciferase reporter plasmid (hsp70-luc, SwitchGear Genomics, Menlo Park, CA, 
product number S112961). At first we wanted to examine the level of gene 
expression when cells transfected using this hsp-construct were heated at 43°C in an 
incubator (no AMF) and then compare the transfection levels to those of cells 
incubated at constant 37.5 °C. Commercial transfection lipid Lipofectamine 2000 
was used to transfect the hsp70 gene-promoted plasmid into the MCF-7 cells. 
Transfected cells were heated at 43°C for 1 h according to the vendor's protocol and 
a luciferase assay was then performed to evaluate the transfection efficiency 24 h post 
heat-induction. Unfortunately we did not observe any encouraging promotion of gene 
expression due to the heat-induction (only - 3X higher levels of expression for the 
heat-treated cells, Figure 2.12). 
The primary problem with this hsp-Iuc vector is related to the prolonged heat 
shock of 1 h required to produce protein expression. This is likely to be a major 
obstacle for NP-mediated AMF-induced gene expression. One hour AMP-induction 
even in cell culture would cause cell death due to over heating from NPs, as 
internalized NP surface will be at much higher than 43°C. Also long time AMF-
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Figure 2.12. Heat-inducible luciferase expression in MCF-7 cells. Transfection was 
performed in 30 mm dish using 0.5 ~g pDNAIdish. Transfection activity was 
expressed as RLU. Lipofectmaine 2000 was used to transfect at vendor's ratio. Cells 
incubated at 37 °C was used as a control. LFT-37/43 °C is the lipoplex formulation 
incubated at 37 ° or at 43 °C. Transfection activity was evaluated using a luciferase 
assay kit according to the vendor's protocol after 24 h of transfection. Transfection 
experiment was performed in duplicates. 
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Thus, the hsp promoter gene is not potent enough to show very high level of 
expression when transfected cells received a heat-induction. Verkis et al. 101 reported 
80-90% GFP expression after 30 min of heat treatment when the cells were 
transfected by their hsp-GFP construct. In their study hsp was taken from the plasmid 
pD3SX, which was purchased from Stressgen Biotechnologies, Victoria, Canada. In 
the work of Smith et al., 103 hsp-Iuc (luciferase reporter) construct showed 53 fold 
enhancement of luciferase expression when cells were induced with heat (temperature 
43°C) for 11 min than the transfected cells incubated at constant 37.5 °C. They also 
used the same source of plasmid to construct the heat shock promoter from Stressgen 
Biotechnologies. Unfortunately, when we pursued obtaining the same vector we 
found that Stressgen Biotechnologies had merged with Enzo Life Sciences, Inc., NY 
and the hsp-vector was discontinued. Our collaborator Dr. Geoffrey Clark (Brown 
Cancer Center, University of Louisville, KY) also tried to contact various authors, 
who had used the vector, but we did get not favorable responses. 
However, further cloning technique could be required to re-engineer the 
present plasmid to improve its expression efficacy at 43°C before use in AMF-
induced hsp-promoted gene expression studies. 
At this stage of the research, we turned our focus to a more achievable goal of 
using AMF-induced hyperthermia to cause drug release from magnetic carriers. The 
details of this research are discussed in Chapter 4. 
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2.3. Conclusion and future directions 
To our knowledge, the MLP and dMLP nano-magnetic gene delivery system 
discussed in this chapter are the first demonstration of attaching lipid sidechains onto 
iron oxide nanoparticles using click oximation methodology. Elaboration of the 
aminooxy-coated particles Np·l described herein into a magnetofection-active vector 
avoids the use of PEl and requires only simple mixing with a hydrophobic aldehyde. 
Using an even more direct approach, we demonstrated that reacting an ammonium 
ion-based oxime ether lipid with iron oxide nanoparticles generated a highly active, 
non-cytotoxic, magnetic transfection vector. Notably, the resultant lipid-coated 
nanovector dMLP functioned in the presence of serum to transfect a representative 
cancer cell line without the assistance of a magnet. According to our literature 
search, our custom made dMLP NPs at present are the only polymer free magnetic 
vectors that can transfect pDNA without magnetic assistance. The poly-L-Iysine 
(PLL) coated magnetic vector prepared by Li et al. (Chapter 1, Table 1.1) is the only 
other reported transfection-active magnetic particle-based formulation thatt does not 
require magnetofection condition. Under magnetofection conditions, dMLP was 
orders of magnitude more active in MCF -7 cells based on luciferase assay than the 
industry-standard transfection agent. The results of our study demonstrate that Fe304 
nanoparticles can function as transfection enhancers for an otherwise transfection-
inactive material. 
Given the emergmg field of in vivo applications, the development of a 
magnetic vector that does not require a magnet for the transfection stage may enable 
applications previously thwarted by less-effective magnetofection. 
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Given a suitable plasmid construct that operates within 15-20 min of heat 
activation, dMLP derived magentoplexes would lead to AMF-induced heat-actuated 
localized gene expression. 
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CHAPTER 3 
CATIONIC OXIME ETHER LIPIDS: 
A VERSATILE CLASS OF GENE CARRIERS 
3.1 Introduction 
3.2 Results and Discussion 
3.3 Conclusion and Future Directions 
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3.1. Introduction 
Cationic lipids and their derived liposomes have become the most well-
studied and widely used synthetic, nonviral gene delivery systems since FeIgner et 
al. 126 first demonstrated DOTMA mediated gene transfer in 1987.127, 128 As discussed 
in Chapter 1, the major limitations of viral vectors, such as associated immune 
responses, limited polynucleotide carrying capacity and high cost,129, 130 make 
















Figure 3.1. Common structural domain of cationic lipids. 
low immunogenicity, the ability to transfect RNA or DNA of nearly unlimited 
size, 131, 132 and ease of formulation techniques of cationic lipid-polynucleotide 
complexes (lipoplex)J33 continue to attract interest aimed at developing safer and 
more efficient cationic lipids for use as transfection agents. 134 
Typical cationic lipid molecules, such as the dual chain lipids DOTMA and 
DOTAP (Figure 3.1), contain a polar, positively charged (DNA binding) head group 
connected to a hydrophobic domain via a linking functionality. These three principal 
structural components of cationic glycerol-type lipids have been extensively studied 
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III efforts to improve lipid-mediated intracellular delivery of polynucleotides to 
mammalian cells. 135 
Over the years many structure-activity relationships have been determined 136, 
l37 to understand the contribution of the hydrophobic domain to transfection 
efficiency, including the variables of chain length, degree of unsaturation, and domain 
asymmetry.138 Although the linker determines conformational flexibility, degree of 
stability, and biodegradability of the cationic lipid, fewer direct structural 
comparisons of changes in the cationic lipid backbone, or linking domain, have been 
reported. The most well-known comparison being that of the diether DOTMA versus 
the diester DOT AP. Among the most studied chemical functionalities comprising the 
linking domain of transfection lipids are the ether, ester, ortho ester, 139, 140 
carbamate,141 amide,142, 143 and phosphonol 44 moieties. 
The use of oxime ether linkers in chemical biology and medicinal chemistry 
have been discussed in Chapter 1 of this thesis. Oxime ether research has increased 
dramatically in the past several years as the benefits of chemoselectivity and methods 
for their exploitation have become better understood. Although oximation has been 
used to attach ligands to transfection lipids, such as the ligation of carbohydrates,I45 
and although an oxime ether-based assembly for siRNA delivery has been reported,146 
no studies have examined the use of the robust yet biodegradable oxime ether linkage 
as the backbone feature of cationic lipids for DNA delivery. 
Our research group's long-term interest on developing lipid-based gene 
delivery vectors139, 147, 148 and interest in click chemistryl49, 150 inspired us to use 
oximation as a facile approach to prepare non-toxic cationic oxime ethers and 
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evaluate their transfection activity in several mammalian cells. Based on the 
promising transfection results using the oxime ether lipid coated NPs (MLPs) 
discussed in Chapter 2, we prepared a panel of oxime ether lipids and evaluated their 
gene expression activity using a conventional co-lipid formulation. A series of novel 
oxime ether lipids were prepared (Scheme 3.1), containing different length of 
hydrophobic chains to study the structure-transfection activity relationships in various 
mammalian cells. The synthesis, characterization and transfection activity of these 
novel oxime ether lipids is presented bellow. 
3.2. Results and Discussion 
Synthesis 
We prepared a panel of cationic oxime ether lipids by reacting bis-(aminooxy) 
ammonium salt 2.2 151 with the hydrophobic aldehydes dodecanal, tetradecanal, or 
(Z)-octadec-9-enal (oleyl aldehyde) in methanol at room temperature to afford oxime 
ethers 3.1, 3.3 and 3.5, respectively (Scheme 3.1). In each case, the lipid was 
obtained as a mixture containing two stereoisomers (diastereomeric ratio ranging 
from approximately 2.3: 1 to 5.3: 1). The major diastereomer has (E)-stereochemistry 
about each oxime C=N bond (as depicted in Scheme 3.1). The minor diastereomer 
has an (E)-oxime ether as well as a (Z)-oxime ether linkage. The (E,E):(E,Z) ratio 
was readily measured by integration of the well separated oximyl proton shifts in the 
IH NMR spectra (Figure 3.2). For example, the oximyl proton shift for the (E)-oxime 
ether side chain in 3.2 occurs at tJ = 7.45 ppm, while the (Z)-isomer shift appears at tJ 
= 6.79 ppm. The isomer ratio was found to be susceptible to a variety of factors 
including exposure to mild acid and heat. The stereochemical integrity of the oxime 
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ether lipids is inconsequential in that isomerization can be expected in vivo. Of 
greater interest, however, is that the oximation approach used to prepare these 
compounds delivers the lipids with intrinsic asymmetry in the hydrophobic domain. 
Nantz et al. 147 and others152 have recently noted the beneficial influence of 
unsymmetrical hydrophobic domains in cationic lipid-mediated DNA transfection. 
Consequently, we used the oxime ether lipids as obtained directly in transfection 
experiments. To probe further the influence of an unsymmetrical hydrophobic 
(E) 
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Scheme 3.1. Synthesis of oxime ether lipid panel via oximtion route. 
domain, we also prepared unsymmetrical analogue 3.4 (Scheme 3.1) by successively 
condensing 2.2 with dodecanal and tetradecanal. The yield of3.4 of was poor (27%) 
compare to others. The yield was not so great in the first step due to formation of 
both bis- and mono-oxime ether lipids and then finally during attachment of the 
second hydrophobic Cw or CJ2-chain to the isolated mono oxime ether we observed 
that column purified fraction was a mixture of 3.1, 3.2, and 3.3. Although, proton 
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NMR looked good, HRMS measurement indicated that the final compound was 
mixture of above three lipids. After careful purification we could only get 27% yield 
of 3.3. Hydrophobic oxime ethers 3.1-3.4 were formulated as cationic liposomes 
using equimolar quantities of colipid dioleoylphosphatidylethanolamine (DOPE) for 
subsequent studies. 
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Figure 3.2. IH NMR of3.2 in CD30D. Oximyl proton shift of E, E isomer: 7.45 ppm 
and Z, Z isomer: 6.79 ppm. 
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Size and charge characterization 
Particle size and zeta potential measurements on the oxime ether liposome 
suspensions revealed that the particles were net positively charged with electrostatic 
potentials in the range of 45-66 mV (Figure 3.3A). Liposomes derived from bis-C l8 
lipid 3.4 were the largest, with particle diameters exceeding 200 nm, and the most 
highly charged. Not unexpectedly, the liposomes derived from the shortest oxime 
ether lipids 3.1 and 3.3 i.e., lipids prepared using dodecanal, had the smallest mean 
diameters, near 150 nm. The trend in particle size versus particle charge correlates 
well for this series of lipids. 
The net charge of lipoplexes derived for the cationic lipids-DOPE, and pDNA 
significantly influence the transfection activity of lipolex formulation. 153• 154 
Complexation of the oxime etherlDOPE liposomes with pDNA (pCMV-Luc) at 
different ammonium nitrogen/DNA phosphate ratios (N:P ratio) gave the 
corresponding lipoplexes. Zeta potential measurements of the oxime ether-derived 
lipoplexes at N:P ratios of 3, 5 and 7 showed high positive values in the range of 31-
53 mV (Figure 3.3B). We observed that at these electrostatic potentials, minimal 
lipoplex aggregation ensued. The oxime etherlDNA lipoplex suspensions were stable 
at concentrations up to 0.33 mg oxime ether lipid per mL beyond one week. Particle 
size measurements of the lipoplexes (Figure 3.3) indicated that the mean effective 
diameter for all N:P formulations remained under 250 nm. Lipoplex size mirrored 
closely the precursor liposome, with the lipoplex generally having an increase in 
diameter by 20-50 nm (Figure 3.4). 
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Lipoplex formulation 
Figure 3.3. A. Zeta potential and mean particle size measurements for oxime ether: 
DOPE liposomes (0.1 mg cationic lipid per mL H20). B. Lipoplex zeta potential 
measurements (lipoplexes were formulated at 0.1 mg cationic lipid per mL H20 with 
pDNA (pCMV-Luc) at different N:P charge ratios). Results are expressed as the 
mean values of n = 3 measurements. 
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lipoplexes at different NIP ratios 
Figure 3.4. Size determination of lipoplexes. Lipoplexes were formulated at 0.1 mg 
cationic lipid/mL H20 with pDNA (pCMV -Luc) at different N:P charge ratios. 
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Transfection activity 
After synthesis and thorough characterization of the lipids 3.1-3.4, and their 
derived lipoplexes, we evaluated the transfecton activity of the lipid panel in human 
breast cancer (MCF-7) and human lung cancer (H1792) cells using a CMV-Iuciferase 
reporter plasmid in the presence of serum (Figure 3.5). Whereas the shortest chain 
lipid 3.1 was essentially ineffective at all N:P formulations examined in MCF-7 cells 
(2000±225 RLU), our studies revealed that transfection efficiency of lipid 3.2 in this 
cell line at an N:P ratio of 7 was notably superior (greater than 2.5 orders of 
magnitude higher activity than the commercial standards) to the commercial 
transfection standard lipofectamine 2000 (3500±990 RLU) as well as to the popular 
transfection formulation jetPrime (2500±209 RLU) (Figure 3.5A). The unsaturated 
lipid 3.4 was also found to be efficacious in MCF-7 cells, although we observed 
greater deviation in the measurement of transgene expression at the higher N:P ratios 
using this lipid (Figure 3.5A). We did not observe an additional boost in transfection 
activity on further amplifying the hydrophobic domain asymmetry by using 
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Figure 3.5. Transfection of cells using lipoplexes formulated at different N:P charge 
ratios: A. MCF -7 cells and B. H1792 cells. Results are expressed as total relative 
light units (RLU). Transfections were performed in 24-well tissue culture plates using 
luciferase reporter construct (pCMV -Luc; 0.025 I-tg / well) with 18 h transfection 
time. Each data point represents the mean value of three separate transfections. Error 
bars show the standard deviation (SD) from th mean. LFT=lipofectamine 2000, 
jetP=jetPRlME. 
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Only lipids 3.3 and 3.4 led to high transgene expression ill H1792 cells 
(Figure 3.5B). In agreement with the observation reported by Nantz et al. 155 and 
Fletcher et al. 156 on lung cell transfections, the presence of unsaturation in the 
hydrophobic domain, such as is present in lipid 3.4, proved to be beneficial for 
activity (Figure 3.5B). Lipoplexes derived from lipid 3.4 effectively transfected 
H1792 cells relative to the commercial controls (60-fold higher activity at N:P=7, 
Figure 3.5B). Interestingly, the enhanced asymmetry of lipid 3.3 resulted in 
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Figure 3.6. Transfection activity oflipid 3.2 in MCF-7 cells using 1 Jlg pDNAIwell 
at N:P = 7. Transfection experiment performed in duplicate. 
On a scale of 1 Jlg DNA per well, transfection of MCF-7 cells in a six-well 
format using lipoplexes derived from lipid 3.2 at an N:P ratio of 7: 1 gave 
approximately a 70-fold higher luciferase expression (as assessed by RLU per mg 
protein) the lipofectamine 2000-derived lipoplexes (Figure 3.6). This result shows 
that the most potent oxime ether lipid 3.2 is effective in high dose and wide range of 





Figure 3.7. MCF-7 cells were transfected with a GFP expression plasmid (0.1 !-tg per 
well in a 24-well plate). Figure are presented as an overlay of green fluorescence 
(visualized by fluorescent microscopy after 20 h of transfection) over the phase 
contrast image: A. Cells treated with pDNA (negative control); B. Cells transfected 
with lipoplexes derived from lipofectamine 2000 (positive control; vendor-
recommended dose=0.25 mL); C. Cells transfected with lipoplexes derived from 
lipid 3 at N :P=7. 
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We also examined the gene-transfer capability of lipids with an oxime ether 
linker domain using a green fluorescent protein (GFP) reporter vector to estimate the 
transfection efficiency in MCF -7 cells (Figure 3.7). Examination of cells by 
fluorescence microscopy using an EVOS fluorescent microscope determined that the 
results were in agreement with those of the luciferase assay. 
Salivary gland cell transfection 
To test the lipids in a non-cancer epithelial cell line, GFP was expressed in the 
salivary gland cell line PAR ClO. This study was completed with the collaboration of 
Professor Sven Gorr's research group at the University of Minnesota, School of 
Dentistry. Lipoplexes were formulated at an N:P ratio of 1.5, the optimal ratio 
determined for lipids 3.1-3.4 in thi~ cell line. GFP expression was evaluated 48 h 
post-transfection. The fraction of transfected cells was quantified by flow cytometry. 
Lipid 3.2 (C14) transfected approximately 40% ofthe cells, lipid 3.1 transfected about 
20%, while lipids 3.3 and 3.4 exhibited less than 10% cell transfection (Figure 3.8A). 
Lipofectamine was slightly more effective in this cell line when used in excess (> 3X 
recommended dose; Figure 3.8A) and comparable to lipid 3.2 when used at the 
vendor-recommended dose (Figure 3.8B). These results suggest that lipids with an 
oxime ether linker domain are suitable for the pDNA transfection of epithelial cell 
lines and, depending on hydrophobic domain composition, competitive with the 
transfection standard lipofectamine. 
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Figure 3.8. GFP expression in PAR ClO cells. A. Cells were transfected (0.2 f-tg GFP 
reporter construct) with lipoplex formulations derived from lipids 3.1·1.4 (N:P=1.5) 
and excess lipofectamine 2000 (LFT; positive control; 1.6 f-tL); B. Comparison of 
lipid 3.2 formulations at the indicated N:P ratio with LFT at the vendor· recommended 
dose (0.5 f-tL). The transfection percentage of GFP expressing cells was analyzed by 
flow cytometry 48 h post-transfection; n = 3. 
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siRNA Transfection 
RNA interference (RNAi) gained a tremendous attention since Fire, Mello and 
colleagues first discovered the ability of double-stranded RNA to silence gene 
expression in 1998.157 Tuschl and co-workers published their celebrated proof-of-
principle experiment demonstrating that synthetic small interfering RNA (siRNA) 
could achieve sequence-specific gene knockdown in a mammalian cell line in 2001 158 
and the first successful use of siRNA for gene silencing in mice was demonstrated for 
a hepatitis C target shortly after. 159 Theoretically, when using appropriately designed 
siRNA, the RNAi machinery can be exploited to silence nearly any gene in the body, 
giving it a broader therapeutic potential than typical small-molecule drugS. 160 Indeed, 
it has already been reported that synthetic siRNAs are capable of knocking down 
targets in various diseases in vivo, including hypercholesterolaemia/61 hepatitis B 
virus (HBV),162 human papilloma virus,163 ovarian-cancerl64 and bone cancer. 165 In 
order for these advances to be implemented in a clinical setting, safe and effective 
delivery systems must be developed. 
We tested the ability of our lipids to transfect epithelial cells with siRNA. 
The previous study revealed that only lipid 3.2 transfected efficiently in P ARC 10 
cells, so cellular "housekeeping" gene glyceraldehyde-3-phosphate dehydrogenase 
was determined by measuring the reduction in GAPDH activity. GAPDH assay is a 
rapid, convenient, fluorescence-based method for measuring the enzymatic activity of 
glyceraldehyde-3 phosphate dehydrogenase (GAPDH) in cultured cells derived from 
human, mouse, and rat. GAPDH is a tetrameric enzyme, composed of 36 kD protein 
subunits. It catalyzes the oxidative phosphorylation of glyceraldehyde-3-phosphate 
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(G-3-P) to bisphosphoglycerate (BPG). The GAPDH gene is generally recognized as 
an ideal target for siRNA. GAPDH gene expression can be readily knocked down in 
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Figure 3.9. Par CIO cells were transfected with siRNA for GAPDH and silencer 
negative control. The enzyme activity was quantified 72 hr after transfection. Each 
data point reflects the mean value of three independent experiments (n=9). Error bars 
show the standard deviation from the mean. 
Silencer® GAPDH Control siRNA). Thus, the efficiency of siRNA delivery can be 
monitored by measuring the reduction in GAPDH mRNA or protein levels in cells 
transfected with GAPDH siRNA relative to cells transfected with a negative control 
siRNA. 
Lipoplexes derived from 3.2 reduced GAPDH activity by 55±9% 
(mean±SEM), while the control lipid, commerciallipofectamine RNAiMAX, reduced 
GAPDH activity by 71±6% (n=9, Figure 3.9). This difference was not statistically 
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significant (p=0.23). These results suggested that lipid 3.2 effectively introduces 
siRNA into epithelial cells. 
Cytotoxicity Evaluation 
We evaluated cytotoxicity of the lipids in MCF -7 and H 1792 cells using vital 
dye trypan blue to stain the dead cells. The number of live cells remaining after 
treatment was calculated as a percentage over the untreated control (Figure 3.l0A). 
Our lipids were found to be less toxic than lipofectamine and jetPrime in both cell 
lines (Figure 3.1OA), with cell viability comparable to untreated cells at all N:P 
formulations examined. 
For PAR C10 cells, the viability was determined by reduction of alamar blue 
(Figure 3. JOB). None of the lipids reduced cell viability significantly compared with 
untreated cells, confirming the low toxicity of lipids with an oxime ether linker 
domain. 
The PARC10 cell transfection experiments were done by Dr. Nandula in Prof. 
GOIT'S laboratory and it is worth mentioned that performance of these lipids were 
reproducible, which is very promising for liposomal formulation. Also, in course of 
our transfection evaluation studies we found that our cationic liposome formulations 
are stable for six months at 4 cC. 
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Figure 3.10. A. Relative cytotoxicity. MCF-7 (dk. bar) and H1792 cells (It. bar) were 
transfected using either lipofectamine 2000 (LFT), jetPrime (JetP) or oxime ether 
lipoplexes at the specified N:P ratio (value in parenthesis). Transfections were 
performed in a 96-well format. Dead and live cells were counted 18 h post 
transfection using a trypan blue stain (n=3); B. Cell viability assay. PAR CI0 cells 
were transfected (N:P=1.5) with lipoplex formulations derived from lipids 2- 5 and 
lipofectamine 2000 (LFT; 1.6 rnL). After 48 h, the cell viability was measured by 
calculating the percentage reduction of alamar blue dye. n = 3 
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3.3. Conclusion and Future Directions 
We have demonstrated that the facile aminooxy-carbonyl click reaction can be 
used to rapidly assemble transfection lipids furnished with asymmetric hydrophobic 
domains. 117 The data show that lipids containing an oxime ether linking domain are 
well tolerated by both cancerous and noncancerous epithelial cells. Furthermore, with 
appropriate tuning of hydrophobic domain composition and N:P formulation, 
ONH2 
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Figure 3.11. Synthesis of prototype oxime ether lipid for cell specific targeting. 
lipoplexes derived from oxime ether lipids readily transfect representative epithelial 
cell lines with excellent activity relative to established transfection agents. Our 
research using the cationic oxime ether lipid panel shows that this functionality is 
suitable choice for linker domain. Given the biological compatibility of oxime ethers 
and their ease of formation, this functional group should find much application in the 
future design of transfection vectors. The ability to transfect epithelial cells could 
have clinical applications, as epithelial surfaces are readily accessible and attractive 
targets for gene therapy protocols that aim to express theraputic proteins in vivo. In 
74 
fact, in vivo study of siRNA delivery in salivary gland using the lipid 3.2 is presently 
undergoing at the Professor Sven Gorr's laboratory. The ability to simultaneously 
transfect pDNA and siRNA with a single reagent now opens potential applications to 
express therapeutic proteins in cells that are simultaneously modified by gene 
knockdown. 
In regards to future direction, we have designed a prototype dual chain oxime 
ether lipid (3.6) that has a free aminooxy group for attaching targeting ligands or 
elements for cell specific delivery (Figure 3.11). The potential of this lipid for 
targeted gene delivery will be evaluated in near future. 
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CHAPTER 4 
IRON OXIDE NANOPARTICLE-MEDIATED, 
AMF-TRIGGERED DRUG DELIVERY 
4.1. Introduction 
4.2. Results and Discussion 
4.3. Conclusion and Future Goals 
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4.1. Introduction 
For therapeutic applications, an external and noninvasive technique of 
actuation can be beneficial to achieve a desired therapeutic effect. The best-known 
examples of such a strategy include using gold nanocages, hollow gold nanospheres, 
or other GNP-based platforms for drug delivery. These vehicles have been used as 
heat-induced drug delivery systems.'66 They represents a class of nano-architectures 
with a hollow interior andlor porous walls that undrgo a photothermal effect while 









Dox release due to polymer 
collapse resulting from laser-
induced heat generation 
Figure 4.1. Schematic illustration of laser-controlled drug release.' 
shape. 167 For example, Yavuz et al. 166 encapsulated the doxorubicin (Dox) into a 
gold nanocage covered with a thermo sensitive poly(N-isopropylacrylamide) 
(pNIP AAM) derivative. On exposure to a laser beam with a wavelength that matched 
the absorption peak of the Au nanocage, light was absorbed and converted into 
thermal energy. These researchers showed that the heat dissipated into the 
surroundings, and the rise in temperature caused the polymer chains to collapse are 
expose in the pores in the nanocage causing release of the pre-loaded Dox (Figure 
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4.1). They also demonstrated that when the laser was turned off, heating 
immediately ceased and the temperature drop brought the polymer back to its 
original, extended conformation, closing the pores and stopping the release. 
In another example, Yang et al. 168 reported a delivery system consisting of a 
poly(lactic-co-glycolic acid) (PLGA) matrix containing (Dox) and a gold over-layer 
on a polymer matrix that also undergoes of a photothermal effect. The temperature 
of the carrier increased due to the surface plasmon resonance (SPR) effect of the gold 










Figure 4.2. Structure of doxorubicin. 
layer when irradiated by near-infra red (NIR) light, and the resultant heat effected 
cargo release from the softened PLGA matrix. 
The concept of heat-triggered drug delivery using hyperthermia generated 
from nano-magnetic carriers has already been discussed in Chapter 1. One important 
advantage of magnetic hyperthermia-stimulated drug delivery using magnetic 
nanoparticles over gold nanoparticle-mediated laser-induced delivery, such as 
described above, is that magnetic particles can easily be viewed by MRI. Secondly, 
laser-induction has the problem of shallow tissue penetrationl69• Where as alternating 
magnetic field (AMF) can penetrate deep into tissue. More importantly, laser-
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induced nanoparticle heating can generate uncontrolled heating (50-700C). 169 
Magnetic hyperthermia is less risky and more controllable than laser-induced heating. 
Given the fact that magnetic hyperthermia already has been examined in clinical 
trials, 170, 171 AMF-induced drug delivery holds immense potential as an externally 
controlled drug delivery platform. 
The recently developed magnetic carriers for AMP-activated drug release are 
described in Chapter 1. In most of the examples, the vehicle consists of a magnetic 
nanoparticle encapsulated in a thermo-sensitive material. The AMF-induced 
hyperthermia (i.e., external stimulus) caused structural changes in these materials and 
these in turn result in cause cargo release (Chapter 1, Figure 1.7) from the vehicles.86, 
172. 173, 174, 175 One problem of these systems is that many thermo-responsive material-
based magnetic carriers suffer from pre-mature drug release at body temperature (37 
°C). Depending on the cargo, this may cause non-specific toxicity in vivo. 
To address the challenge of premature cargo release, we aimed to assemble a 
Fe304 nanoparticle (NP)-based delivery platform functions without the need for a 
third component's structural or conformational change. In other words, our goal is to 
design a thermosensitive, polymer matrix-free magnetic drug carrier that will respond 
to an external AMF-stimulus to cause magnetic hyperthermia-triggered drug release. 
Thus, the key innovation over existing carriers is vehicle simplification - no thermo-
responsive materials will be incorporated. 
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4.2. Results and Discussion 
Development of magnetic carriers 
We have chosen the potent, anti-cancer drug doxorubicin (Dox, Figure 4.2) as 
our model drug. Dox is an anthracycline antibiotic that consists of an aglycone, 
hydroxylated quinine, and daunosamine sugar residue. Dox is a leading anti-cancer 
drug because of its potent and broad spectrum of activity against diverse types of 
cancer.
176 However, the efficacy of Dox treatments are severely impeded due to its 












To achieve our goal we strategized three routes to load Dox onto the Fe304 
NP surface. As learned from our MLP/dMLP-mediated gene delivery program, we 
first devised a stepwise loading of Dox onto the NP surface. In this route (Scheme 
4.1), we first coated the NPs with the quaternary ammonium aminooxy reagent 2.3 to 
synthesize Np·AO by simple mixing of the NPs with excess 2.3 (ca. 3.5 wt. 
equivalents). Absorption of charged ligands on nanoparticle surfaces are well known 
in the literature. 180, 181 , 182 Recently Berret et al. 183 demonstrated that negatively 
charged y-Fe20 3 nanparticles can be coated and consequently stabilized using block 
copolymers containing a cationic quaternary ammonium group. The mechanism is 
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based on electrostatic attraction between the oppositely charged entities. Alcoholic 
hydroxyl groups are also well known for stabilizing iron oxide nanoparticles, e.g., 
dextran coated nanoparticles are well characterized and even commercially available. 
We hypothesize that the positive charge of the cationic aminooxy reagent as 
well as its hydroxyl groups are responsible for the efficient surface coating, specially 
since the NPs are negatively charged (~-potential = -30 mY). ~-potential 
measurement of Np· AO revealed that particles were partially neutralized at -19 m V. 
We demonstrated previously (Chapter 2) that cationic aminooxy reagents can be used 
as surface modifiers of NPs and that the aminooxy groups are available for ligation 
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subsequent conjugation of Dox Via an oximation reaction to yield sNp·AO·Dox 
(Scheme 4.1). Dox has multiple carbonyl groups for reaction with aminooxy 
functionality. 
The fact that cationic oxime ether lipids tend to bind well to our NPs (Chapter 
2), inspired us to devise our second formulation route. We first synthesized a novel 
cationic oxime ether conjugate of Dox at the C-13 ketone position (Dox· AO, Scheme 
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4.2). To synthesize Dox·AO we modified the method described for synthesizing a 
Dox-maleirnide conjugate at C-13 position as described by Kruger et al. l84 In brief, 
2.3 and Dox were reacted in 0.1 % trifluoro acetic acid in anhydrous methanol for 96 
h at room temperature under nitrogen. The solvent was evaporated and Dox·AO was 
purified via recrystallization from hot acetonitrile. Dox·AO was characterized by IH 
NMR, I3C NMR and HRMS. I3C NMR spectroscopy revealed that oximation had 










Scheme 4.3. Preparation of Dox loaded magnetic nanoparticie formulations. A. Direct 
loading of Dox·AO. B. Only Dox. loading. 
213.2 ppm in Dox·HCl to 162.6 ppm in the conjugate. In contrast, the I3C NMR 
chemical shifts of the quinone carbonyl carbons (C-12 and C-5) were essentially 
unchanged (Figure 4.3). The two extra signals between 50 and 55 ppm and three 
extra signals between 60 and 70 ppm (Figure 4.3) correspond to the added carbons of 
2.3. Also, chemical shift of alpha carbon to the amine group of the Dox·HCl and 
Dox·AO remain essentially unchanged. HRMS analysis revealed the existence of 
Mlz = 1 species. After synthesizing Dox·AO, we loaded this cationic analog onto 
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the NPs directly (Scheme 4.3A) to furnish dNp·AO·Dox. Reaction of NP and 
Dox·AO in DMSO at room temperature for 12 h, followed by two magnetic 
separations provided dNp·AO·Dox. After the first magnetic separation, the isolated 
NPs were washed with methanol, and after the second wash we did not observe any 
red colored supernatant indicative of free Dox-conjugate. 
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Figure 4.3. Comparison of the l3C NMR spectra of Dox·HCl and Dox·AO in 
CD30D. 
84 
The fact that Dox-HCl (Figure 4.1) is a hydrochloride salt and has a sugar 
moiety encouraged us to examine a third strategy, the preparation of NP-Dox 
(Scheme 4.3B). 
We loaded Dox-HCl directly onto NPs assuming that the innate charge 
attraction, and hydrogen bonding would be sufficient to keep Dox associated with the 
NPs. 
DOX=NOV .. ----. , , , ,'+/\ " 
; NOH, 






We assume this is the region 'binding' 
to the NP, so the footprint of this should 
be calculated 
/\ ~N OH 
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A good surrogate of 
above binding domaain 
Figure 4.4. Possible binding domain of Dox-AO. 
In each of the NP functionalization steps we purified and isolated end-
functionalized particles by employing a magnetic separation technique that involved a 
methanol washing followed by another magnetic separation. The collected 
supernatant that contained un-separated drug-loaded NP colloids were centrifuged at 
10000 rpm (4°C for 15 min) to purify from unreacted Dox-AO and resultant NP-
pellet was mixed with magnetically separated NPs. The dry weight of purified (i.e., 
multiple washed) drug-loaded formulation provided the loading efficiencies. The 
direct formulation (dNP-AO-Dox) showed maximum loading efficiency (~ 0.37 
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~mol/mg NP). A considerable amount of conjugate was also associated with the NPs 
using the stepwise method (- 0.3 ~mol/mg NP, Table 4.1). The NP-Dox formulation 
also indicated loading of Dox onto NP surface (- 0.l5 ~mol/mg NP, Table 4.1). 
Loading calculation revealed that nearly 580 Dox-AO moleculeslNP. Loading 
calculation revealed -580 Dox-AO moleculeslNP. A footprint calculation of 
Dox-AO (number of molecules/ NP surface area), assuming the ammonium ion head 
group binds to the NP surface, (Figure 4.4) revealed that approximately 1450 
Dox-AO molecules can be attached to the NP surface. We hypothesize that the Dox 
molecules likely are not lying flat on the particle surface, but actually are attached to 
the surface via the polar linker groups (Figure 4.4). Thus, we calculated the footprint 
using surface area ofa close surrogate 4.1 (Figure 4.4) of binding moiety of Dox-AO. 
Since the aminooxy domain is smaller than the Dox molecule, more drug molecules 
are predicted to be bound to the NP surface. This accounts in part for the smaller 
quantity of Dox that was measured in the NP-Dox formulation relative to the 
NP-AO-Dox formulations. 
86 
Zeta potential measurements 
We performed zeta (~) potential measurements to evaluate the surface charge 
of the Dox-Ioaded nano-magnetic drug carriers (Table 4.1). Surface potential of 
sNp·AO·Dox was increased to slightly positive (+3 mY) from -27 mV (NP surface 
potential) and it became moderately positive in dNP·AO·Dox to +17 mV (Table 4.1). 
Dox·HCI attachment onto the NP surface also partially neutralized the NP surface 
Formulation Zeta potential Average AVel'age loading Loading footprOOf: 
(mV) loading (no. of drug no. of drug 
"mollmg NP conju~ate moleculeslNP 
moleculeslNP) sW'face area 
NP -27~1.7 - - -
NP·Dox -20+-2.3 0.15 235 587 
sNP·AO·Dox 3~.1 0.3 470 1175 
dNP·AO·Dox 17.1±3.1 0.37 580 1450 
Table 4.1. Zeta potential of NPs and drug loaded NPs (concentration: 0.3 mg NP/mL 
PBS, n=3); and average loading of Do x as detennine.d by weight differentials. 
potential to -20 m V. Charge neutralization of NPs indicated better attachment of 
cationic oxime ether Dox analog to the negatively charged NP surface. 
AMF -induced NP heating 
Next we evaluated the AMF-stimulated heating of our NP-drug formulations. 
Local temperature of surrounding media containing NP-formulation suspension 
increased when dNp·AO·Dox (2.5 mg/ rnL NP by wt.) was subjected to an external 
AMF (Easy Heat, Amritherm; frequency: 203 kHz, power: 350 A, 5 turn coil with 5 
cm ID) for 18 min. The AMF parameters were chosen by noting previously reported 
magnetic NP-derived hyperthermia-induced drug delivery demonstrations. Brule et 
al. 86 applied 700 kHz frequency to release Dox from an alginate-based magnetic 
microsphere. Zink and coworkers demonstrated cargo release from magnetic carriers 
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using an AMP applicator at 500 kHz.185 Importantly, frequencies greater than 400 
kHz are known to cause nonspecific heating in tissue. 186 Finally, Jordon et at. 187 
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Figure 4.5. AMP-induced hyperthermia of dNP-AO-Dox in PBS (2.5 mg NP by wt.)/ 
mL. Temperature of the surrounding solution was measured every 3 min using a fiber 
optic temperature probe. n = 3. 
With above demonstration, we decided to use an intermediate frequency of 
200 kHz that can be generated readily using our 5-turn coil AMP applicator. The 
power (350 A) was automatically set for this frequency. AMP-induction was started 
after temperature of the medium reached at 37.0 °C and the temperature of the 
surrounding solution was measured at every 3 min using an optical fiber temperature 
probe (Neoptix Inc., Quebec, Canada). Our studies showed that the thermal energy 
generated by the NP formulation on AMP -exposoure elevated the solution 
temperature from 37 °C to ~43 °C within 12 mins. Little change occurred on 
continued AMP-exposoure (Figure 4.5). 
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AMF -induced Dox release 
Drug release studies using our NP formulations were performed following the 
same AMF parameters as mentioned above. The Dox conjugate release study was 
performed according to methods described in papers published by Brule175 and Luo et 
al. 188 Dox release was estimated every 3 min using a UV -spectrophotometer 
measurements taken at 480 nm. 480 nm is the Dox absorbance of the quinone 
system. Every 3 min 10 ilL of supernatant was aliquoted and diluted to 1 mL for 
spectrometric reading. 
We observed that an AMF-stimuli considerably increases Dox or Dox-
conjugate release from the magnetic carriers (Figure 4.6A) than what was released by 
mere incubation at 37.5 °C. Both the dNP·AO·Dox and dNp·AO·Dox formulations 
released ~65% of their payload by 12 mins of AMF induction. The Np·Dox 
formulation released ~55% of cargo at the same point of time (Figure 4.6A, green 
line). Although s/dNp·AO·Dox released same average % of drug conjugate, they 
released different amounts of drug since the loadings differed (Figure 4.6B). 
According to our observations, no substantial drug release was detected at 37.5 °C 
from the carrier (Figure 4.6C). It is evident from AMF-induced NP heating and drug 
release studies that maximum average local temperature of 43°C can be achieved at 
1 i h mins, and this duration of AMF -exposoure can trigger ~65% of cargo release 
from the nano-magnetic vehicles. We also predicted that these NP formulations 
would not exhibit cytotoxicity due to their lack of their at 37°C, and thus the 
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Figure 4.6. Drug release profile. A. % of AMF-induced Dox and Dox·AO. Drug 
release was calculated every 3 min using UV -spectrophotometer measurements taken 
at 480 nm. Every 3 min, 10 "",L of supernatant was removed and diluted to 1 rnL for 
spectrometric measurement (n = 3). B. mg of Dox released per mg of NP during 
AMF-stimulation (n = 3). C. Drug release at 37.5 °C; no AMF-induction (n = 3) 
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Cytotoxicity studies 
Encouraged by our AMF-promoted NP heating and drug release studies we 
set out to investigate AMF-induced cytotoxicity of the NP formulations in a breast 
cancer cell line (MCF-7). MCF-7 cells plated in a 30 mm dish at 4XI05 cells/ dish 
were grown to 50-60% confluence. After treatments with varying amounts of the NP 
formulations (0.25 mg, 0.5 mg and 0.75 mg NPs./ dish), the cells were incubated for 1 
h at 37.5 °C before exposoure to the AMF. Dishes containing cells treated with 
NP·drug formulations and untreated (control) were placed at the center of the 
Figure 4.7. AMF generator: EasyHeat, Ameritherm, NY. 
induction heater coil (Figure 4.7). Each dish was then subjected to an AMF for 15 
min using the same parameters as described above. Cells treated with Dox (0.5 !-lmol) 
and Dox·AO (0.5 !-lmol) served as positive controls. 
As determined by the assay using the National Cancer Institute (Frederick, 
MD) 60-cancer cell line screen, we found that Dox·AO was cytotoxic towards MCF-
7 cells (Figure 4.8 and Figure 4.9B). In regards to the other control experiments, cells 
treated with NP formulations were incubated at 37.5 °C for 48 h to evaluate the 
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cytotoxicity in the absence of AMF -exposure. We did not observe any abnormal 
behavior of the untreated cells towards AMF induction (Figure 4.9B). Also, 
aminooxy coated NPs (NP·AO) were found to be nontoxic and surprisingly showed 
no cytotoxicity even in the presence of AMF-exposure. Our studies indicated that 
none of the NP-based Dox formulations (s/dNP·AO·Dox or NP·Dox) were cytotoxic 
in the absence of AMF-exposure; however all the NP formulations displayed 
significant cytototoxicty upon AMF treatment (Figure 4.9B). We found that the 0.5 
mg dose (NP by wt.) was the most effective dose for AMF-induced cell death. Cells 
treated with same amount of s/dNp·AO·Dox (NP by wt.) and exposed to an AMF 
showed different levels of cytotoxicty. With AMF-exposure cell viability decreased 
to -15% when the cells were treated with dNp·AO·Dox at the 0.5 mg NP dose 
whereas cell viability decreased to -27% when cells were treated with sNp·AO·Dox 
at the same dose. As discussed previously, dNp·AO·Dox has more conjugate (in 
terms of mg) loaded on the NP surface than stepwise formulation, which in turn 
released more conjugate on AMF-irradiation. Releasing more drug-conjugate from 
dNP·AO·Dox than sNp·AO·Dox makes dNp·Np·Dox more cytotoxic in the 
presence of AMF-induction. We also hypothesized that the higher positive ~­
potential of the dNp·AO·Dox promoted its cellular internalization. The Np·Dox 
formulation was also active and demonstrated -50% cell inhibition when stimulated 
by AMF (Figure 4.9B). The 0.75 mg NP dose showed aggregation in the cellular 
media and was not evaluated further. 
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Figure 4.8. NCI 60-cancer cell line screen of Dox·AO (We thank Dr. Paul Grothaus 
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Figure 4.9. AMF-induced cytotoxicity in MCF-7 cells. A. Experimental setup of 
AMF-induced drug release in MCF-cells; cells were plated in 30 mrn dish. B. Cell 
viability; Control groups (cells treated with NP formulations but no AMF-induction) 
were incubated at 37.5 °C for 48 h. NP formulation treated cells and only cells were 
induced by AMF for 15 min with same parameter as before. 0.5 and 0.25 mg 
formulation (NP by wt.)/ dish was added to cells; 0.5 /-lIDol of Do x and Dox·AO were 
positive controls. Cell viability was evaluated after 48 h of treatment using trypan 
blue assay. 
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Finally we monitored Dox and Dox·AO release in the MCF-7 cells pre-AMF 
and post-AMF exposure using fluorescence microscopy (EVOS, Advanced 
Microscopy Group, W A). Dox is easily observed using fluorescence microscopy due 
its red fluorescent color and it appears as a bright red signal. Figure 4.1 OB shows the 
fluorescence image of MCF -7 cells treated with Dox. Figure 4.1 OC suggests there is 
no Dox release from NP·Dox before AMF-treatment. As clear from Figure 4.lOD, 
AMF exposure triggers Dox release from the magnetic vector. 
Very interestingly, when the above experiment was performed usmg 
dNp·AO·Dox we did not observe any indication of DoxIDox·AO release in the cells 
(Figure 4.10E) post-AMF treatment, but significant cell death occurred suggesting 
release had occurred. This incident of fluorescent quenching was also observed when 
cells were treated with only Dox·AO (Figure 4.lOF). We explain this phenomenon 
by hypothesizing that Dox·AO binds its intracellular target DNA more effectively 
than DOX,189, 190 which ultimately quenches the fluorescence of Dox. AO more 
effectively. The fluorescence quenching is not due to the formation of the cationic 
oxime ether linkage. The fluorescence intensity of both Dox and Dox· AO at the 
same concentration is simmilar (Figure 4.11). Our results indicated that fluorescence 
intensity was same for Dox and Dox·AO (Figure 4.11). Further more, when we 
analyzed the supernatant from AMF-induced dNp·AO·Dox using HRMS, data 





Figure 4.10. Fluorescence images of MCF-7 cells. A. Cells treated with Dox. B. 
Cells treated with Dox·AO. C. Cells treated with Np·Dox (No AMF). D. Post-AMF 
treated with Np·Dox. E. Cells treated with dNp·AO·Dox (0.5 mg NP by wt. , No 
AMF). F. Post-AMF treated with dNp·AO·Dox (0.5 mg NP by wt.). 0.5 !-lmolofDox 
and Dox·AO was added to the cells. Fluorescence images were taken after 6h of 
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Figure 4.11. Fluorescence spectra of Dox·HCI and Dox·AO (1 mmol m 
methanol). Y-axis: fluorescent intensity and X-axis: wave length (nm). 
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We performed a fluorescence measurement of the Np·Dox formulation. After 
synthesizing NP·Dox, fluorescence activity was measured in ethanol using a 
fluorescence plate. The fluorescence intensity of Np· Dox was 41 % less than the 
fluorescent intensity measured for free Dox-HCI (Figure 4.12). We hypothesize that 
the reduction is in part due to the spherical nature of particles, and one would expect 
the edges of the sphere would receive less excitation than the face directly positional 
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Figure 4.12. Fluorescence intensity of Do x and NP-Dox. 1 mmollL Dox 
in ethanol. 
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4.3. Conclusion and future directions 
We developed a binary (NP + pharmaceutically active coating) external 
stimuli-responsive magnetic drug delivery system in which a drug conjugate is loaded 
onto NPs via simple electrostatic attraction and hydrogen bonding. Subsequent AMF 
exposure breaks the electrostatic attraction forces as the NPs heat, thus constituting a 
stimuli-responsive drug release. The temperature ofNP surface is high enough (> 43 
°C) to promote ammonium drug conjugate release from NP surface.191 This binary 
nano-platform does not depend on a third variable, e.g., structural change of polymer 
due to NP heating for cargo release. 
We demonstrated that the cationic oxime ether analog of doxorubicin can be 
attached to Fe304 NPs via simple mixing. The loaded NP formulations are nontoxic 
to cells. However, on application of an AMF, the Dox payload released from the 
particles. The magnetic nanoparticle delivery system was functionally demonstrated 
using MCF -7 cells and shown to be effective when the external AMF stimulus was 
applied. Our AMF-applicator parameters are well within the safe range for treatment 
of mammals as described previously and in present189 clinical trials of magnetic 
hyperthermia. 
The future of our magnetic delivery system largely depends on animal 
studies. Effect of various oxime ether drug-conjugates (e.g.; one, two, or three 
hydrooxy ethyl groups on cationic aminooxy reagents) on drug loading and release 
will be performed in near future. The effect of AMF-applicator parameters on NP 
heating also remained to be optimized in near future, as the focus of the research 
shifts to animal studies. 
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CHAPTERS 
BIOANALYTICAL APPLICATIONS OF 
CATIONIC AMINOOXY REAGENTS 
5.1. Introduction 




This chapter describes my contributions to a collaborative bioengineering 
project focused on the development of a microchip-based human breath analyzer for 
detection of volatile organic compounds (VOCs). The project is a collaboration 
among three research groups, those of Professors Nantz and Higashi (Chemistry) and 
Fu (Chemical Engineering). Although this project is not directly related to my thesis 
focus of drug delivery, the research does exploit the cationic aminooxy compounds 
described earlier. 
The microreactor fabrication, functionalization, and breath analyses were 
performed by Dr. Xian Fu and his graduate student Mingxiao Li (Chemical 
Engineering, University of Louisville). 
Analysis of exhaled breath has become an important research arena because 
of its potential and applicability in noninvasive health diagnosis, metabolite 
bioinformatics, and drug discovery.192, 193,194,195,196 The gaseous portion of breath is a 
complex mixture of atmospheric gases, water vapor, and trace volatile organic 
compounds (VOCs). In 1971, Pauling reported the first gas-chromatographic analysis 
of breath, and the study revealed the presence of a large number of VOCs in human 
breath. 197 A number of recent publications l98, 199,200,201 suggest that the analysis of 
exhaled breath promises to be a non-invasive diagnosis for early detection of 
particulate cancers since some VOCs in exhaled breath represent metabolic output of 
cancer tissues and cells. 
One of the most critical challenges for the analysis ofVOCs in exhaled breath 
is ultra-trace concentrations of VOCs and interference of complex gas mixtures. 
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Exhaled breath contains more than 200 VOCs. Recently, several reports indicate that 
some ketones and aldehydes in exhaled breath could be used for the diagnosis of lung 
cancer at an early stage. 195, 196 
Carbonyl metabolites are produced in biochemical pathways as intermediates 
and some can be unique to a given pathway or process. However, even common 
carbonyl metabolites can be attributed to specific processes when stable isotope 
labeled substrates are metabolized (e.g. by human subjects) and detected by mass 
spectrometry or NMR.202, 203 Volatile ketones and aldehydes are also generated from 
damaging oxidative reactions, such as lipid peroxidation.204, 205 Therefore, 
development of a new method for analysis of ketone and aldehyde VOCs in exhaled 
breath has a tremendous potential to fulfill the breath analysis promises. 
Ketones and aldehydes can be detected by proton transfer reaction mass 
spectrometry (PTR_MS),206, 207, 208 or selected ion flow tube mass spectrometry (SIFT-
MS) without any preconcentration process.209, 210 Most recently, solid phase 
microextraction (SPME) with adsorbed 0-2,3,4,5,6-
(pentafluorobenzyl)hydroxylamine hydrochloride (PFBHA) has been used for 
analysis of aldehydes in exhaled breath by gas chromatography-mass spectrometry 
(GC_MS).195, 196 SPME is a popular preconcentration method introduced a decade ago 
as a rapid extraction technique for analysis of volatile compounds from a variety of 
matrices.2II However, the smaller surface area of the SPME polymer extraction 
phase and physical adsorption of aldehyde PFBHA onto SPME for its capture makes 
it is also extremely difficult to improve upon, or even determine the volume of air that 
is actually sampled by the SPME fiber. The quality of the fibers depends on the 
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manufacturer, and the performance varies from batch to batch. Derivatization of 
ketones and aldehydes by reaction with 2,4-dinitrophenylhydrazine has also been 
used for analysis of carbonyl compounds in exhaled breath,z12 which has the 
advantage of converting volatile aldehydes and ketones into stable, easy-to-handle 
non-volatile analytes. However, this class of reagents was not designed to aid in 
detection by modern ultra-sensitive ion sources such as nanoelectrospray FT-ICR-
MS. 
To address the above stated problems, we aspired to design a breath analyzer 
based on a microreactor approach to capture gaseous ketones and aldehydes from 
exhaled breath using a chemoselective oximation technique. 
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5.2. Results and Discussion 
Proof of concept 
To engineer a breath analyzer silica microchip-based aminooxy loaded, we 
first designed a simple bench top proof-of-concept experiment, wherein silica gel (1.5 
g) was first loaded with cationic bis-aminooxy reagent 2.2 (35 mg, 0.12 mmole) in 
1:5 MeOH:dichloromethane (steps a and b; Scheme 5.1). An ampoule of acetone-d6 
(1 mL) was placed inside of the RB containing dried silica gel coated with 
quaternary aminooxy salt 2.2 and then RB was sealed to protect the functionalized 
silica gel from laboratory ambient acetone (or other vapors containing ketones or 




a. 1:5 MeOH:DCM 
1.5 h 
b. remove solvent 
c. expose to ~{). 
acetone-d6 
ampoule. . acetone-d6 ampoule 
d. incubate18 h 
then remove 
ampoule 
e. wash substrates 
from support 
1 :20 MeOH:DCM 
filtration f. Analyze 
Filtrate analyzed 
by FT-ICR-MS 
Figure 5.1. Schematic diagram of acetone-d6 capture. 
aminooxy coated silica 
for adducts by first eluting all materials from silica (stage e and f, Scheme 5.1) and 
then analyzed by FT-ICR-MS. MS analysis revealed that the aminooxy-coated silica 
gel indeed captured acetone-d6 vapor efficiently (Figure 5.2). 
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Figure 5.2. FT-ICR-MS spectrum of eluted aminiooxy-acetone-d6 adduct. 
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Microreactor design 
With this result in hand, Dr. Xian Fu' s research group prepared a microreactor 
fabricated on 4 inch-silicon wafer using standard microelectro-mechanical systems 
(MEMS) fabrication technology? 13 Figure 5.3 shows an optical micrograph of the 
fabricated microreactor. The fabricated microreactor is the size of a penny (Figure 
5.3B). 
The micropillars have high-aspect-ratio with dimensions of 50 fA-m X 50 fA-m X 
250 fA-m created by dry reactive ion etching silicon. The distances from center to 
center of the micropillars are 100 fA-m. The flow channel size is 7 mm X 5 mm. The 
A B 
Figure 5.3. A. Optical micrograph of a fabricated microreactor with thousands 
internal micropillars. B. Fabricated micropillar on a silicon wafer. 
total empty space in the microreactor is about 5 fA-L. There are more than five 
thousand square micropillars within the microreactor corresponding to a total 
micropillar surface area of about 260 mm2• For introduction of the capture coating 
and eventual gaseous samples, the inlet and outlet of the micro reactor were connected 




The surface of the micropillars was functionalized usmg quaternary 
ammomum aminooxy salt 2.1 151 (abbreviated as ATM in this collaboration) for 
chemospecific ketone or aldehyde capture (Scheme 5.1). The surface 
functionalization of the channels and micropillars by A TM ions was performed by 
infusing a known amount of the A TM iodide salt in methanol solution into the 
microreactor channel from one connection port followed by evaporation of the 
solvent under vacuum. The slightly negative surface charge of silicon oxide 
micropillars enforces the close association of A TM with the solid support, which is a 
benefit of including the quaternary ammonium group in the design. 
Capture efficiency 
To test the capture efficiency of the microreactor, measured amounts of 
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Scheme 5.1. ATM oximation traps ketones and aldehydes in the microreactor. 
methanol) were injected into a high purity (99.9999%) helium gas flow stream 
passing through the microreactor. As illustrated in Scheme 5.1, the adsorbed A TM 
on the micropillars react with gaseous ketones and aldehydes via oximation to capture 
the analytes as oxime ether adducts. 
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Figure 5.4 shows the schematic test setup for preconcentration of ketones and 
aldehydes by the microreactor. In brief, various quantities of deuterated acetone, 
from 0.271 nmole to 0.271 mmole in methanol, were added to the 20 mL vial to 
evaporate into helium flowing through the vial and then the microreactor. The vial 
had a Teflon lined rubber septum connected to both helium source and the 






Figure 5.4. Schematic flow diagram of the preconcentration setup. 
avoid bias from any environmental trace acetone contamination. The microreactor 
operated at an inlet helium pressure from 15 to 25 psi. The flow rate of helium 
through the microreactor was 2 to 5 mLimin. After addition of acetone-d6 to the vial, 
helium flowed for at least 30 min to allow completion of the acetone-d6 transfer into 
the microreactor. After preconcentration, the microreactor was disconnected from the 
setup. Then, the microreactor was eluted by flowing 10 flL methanol portions 
through the microreactor into a septum-sealed glass vial; each aliquot was analyzed 
separately to gauge elution efficiency via mass balance. The collected elution 
solutions were directly analyzed by nanoelectrospray FT-ICR-MS for 5 min. 
Figure 5.5A shows a typical FT-ICR-MS spectral region that has oximation 
product of ATM with acetone-d6 (165.18688m1z ion) as well as unreacted ATM 
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cations (119.11793 m/z ion). Greater than 98% of total reacted ATM and unreacted 
A TM was collected from the microreactor with the first 10 mL methanol aliquot. 
There was no trace detectable A TM and A TM-acetone-d6 after flushing a total 40 !-lL 
methanol through the microreactor. Thus, the transfer efficiency exceeded 98% for a 
rapid 5 min, 10 !-lL elution at the benchtop, requiring no specialized equipment other 
than septum-capped vials and a syringe. The total analytical recovery of the acetone-
d6 dosage was >98%. Figure 5.5A also indicates that trace acetone contamination 









A TM-acetone d6 
llUSCIII 
Figure 5.5. A. Positive-ion nanoelectrospray FT-ICR-MS spectrum of 
preconcentrated deuterated acetone from the microreactor. B. A typical FTICR-MS 
spectrum of an exhaled breath preconcentrated by the A TM-coated microreactor. 
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Ketone and aldehyde capture in exhaled human breath 
Further testing was performed using exhaled breath as a prelude to future non-
invasive health diagnosis methods. After approval by the Internal Review Board at 
the University of Louisville and after having obtained written informed consent, 
exhaled breath samples were collected from nine voluntary healthy non-smoking 
subjects in the age range from 20 to 40. The subjects breathed lL breath air into one 
liter Tedlar bags. A mixed alveolar breath and non-alveolar breath was collected. The 
Tedlar bags were purchased from Supelco (Bellefonte, PA, USA). The bags were 
tested free of ketone and aldehyde contamination. After collecting exhaled breath, 
the sample bag was connected to the inlet of the microreactor through septa and the 
silica tube. The outlet of the microreactor was connected to an oil free vacuum pump. 
Each microreactor was loaded with 365 nmole ATM. After the breath air in the 
sample bag was evacuated, the microreactor was disconnected from the flow line and 
then eluted with methanol as described above. A 8mL solution containing 2.32 
nmole acetone-d6 completely reacted with A TM in methanol was added into each 
eluted sample for analysis by FT-ICRMS. The ATM-acetone-d6 adduct served as the 
internal reference to estimate captured amounts of ketones and aldehydes. Fig. 5.5B 
shows a typical FT-ICR-MS spectrum of exhaled breath. C} to Cl2 ketones and 
aldehydes were detected. 
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5.3. Conclusion 
The results of this work show that a microreactor-based aminooxy coating 
efficiently oximates gaseous carbonyl species for practical analysis of ketone and 
aldehyde VOCs. The designed microreactor features thousands of micropillars that 
uniformly distribute gas flow to maximize the interactions with ketones and 
aldehydes in the gas flow, resulting in capture efficiencies higher than 98%. 
Moreover, the key inclusion of a quaternary ammonium group in the design of the 
coating of the micropillar surface greatly enhances electrospray MS analyses. Simple 
elution of the entire microreactor coating including all captured analytes eliminates 
sample transfer problems that have plagued previous preconcentration approaches. 
This complete elution is enabled by the use of direct infusion nanoelectrospray 
FTICR-MS, which has the resolution to avoid interference of analytes by the capture 
phase. 
Since the FT-ICR-MS instrument is very expensive (present price $ 1M) and 
not common in many diagnosis facilities, we also considered applying this approach 
Figure 5.6. Structure of AMA (5.1). 
to the more widely used GC-MS technique. To make the miroreactor-based breath 
analyzer more available and cheap, we have functionalized microreactors using the 
commercial neutral aminooxy reagent ortho-(2-morphilin-4-yl-ethyl)-hydroxylamine 
(or AMA, 5.1, Figure 5.6) to detect the oximated adduct by less expensive GC-MS. 
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Initial studies revealed that capture efficacy of 5.1 is compareble to ATM. This work 
. . 
IS ongomg. 
Various cationic and neutral aminooxy-based reagents will be synthesized and 
will be tested for ketone/aldehyde capture using microreactor. The ATM-Ioaded 
microchip is now being tested for analyzing vapor generated from the lung cancer 
tissue and cell culture samples. The micrometer size of the chip can be advantageous 
for testing various unique atmospheres of cells. Due to the high sensitivity and easy 
engineering, this chemoseletive microreactor-based vapor analyzer has great potential 
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All solvents and reagents used in this thesis were reagent grade and were used 
as received unless otherwise indicated. All nanoparticies and nanoparticie 
formulations were synthesized using HPLC grade methanol (Sigma-Aldrich). Dry 
THF and CH2Clz were obtained from SPBT-101 Bench Top Solvent Purification 
System (LC Technology Solutions, Inc., USA). Anhydrous DMSO and methanol 
were purchased from Sigma-Aldrich. Doxorubicin (Dox·HCI) was purchased from 
Selleck Chemicals (TX, USA). 
Column chromatography was conducted on silica gel (Si02, Mesh size: 230-
400 mesh, EMD Silica Gel 60). Thin layer chromatography was performed on 
precoated silica plates (EMD Silica Gel 60 F254). UV active compounds were 
visualized by UV light (254 nm). The TLC plates were stained using iodine, or p-
anisaldehyde, or with phosphomolybdic acid. High performance liquid 
chromatography (HPLC) purification was performed using a Waters Delta 600 with a 
dual wavelength (214 and 254 nm detector) UV detector (Waters 2487 Dual 
Wavelength Absorbance Detector). 
NMR spectra were recorded with a Varian MR eH 400 MHz, BC 125 MHz) 
or with a Varian Inova eH 500 MHz, I3C 100 MHz) spectrometer. IH and I3C NMR 
spectra of Dox·HCI and Dox·AO were recorded using a Varian VNMRS 700 
spectrometer eH 700 MHz, I3C 176 MHz). Infrared spectra were recorded on a 
Mattson Galaxy Series FTIR 5000 spectrometer. Fluorescent spectrometric 
measurements were performed using a Perkin Elmer LS55 Fluorescence 
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Spectrometer. High resolution mass spectrometry (HRMS) of the compounds were 
performed at the University of Louisville, Center for Regulatory and Environmental 
Analytical Metabolomics (CREAMM) facility using Thermo LTQ-FT instrument. 
Liposome and nanoparticle formulations were prepared in ultra pure water 
(Milipore). Sonication was performed using bath sonicator purchased from 
Laboratory Supplies Co., Inc., Ithica, NY. Zeta potential and particle size analyses 
were conducted using ZetaP ALS dynamic light scattering detector (Brookhaven 
Instruments Corporation; Model 90 Plus). 
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6.2. Experimental procedure of Chapter 2 
Synthesis 
N-(2-( aminooxy)ethyl)-N,N ,N-trimethylammonium iodide (2.1) 
To a solution of triphenylphosphine (15.3 g, 58.3 mmol) and N-
hydroxyphthalimide (9.50 g, 58.3 mmol) in THF (200 mL) at 0 °C was added 
dropwise N,N-dimethyl-ethanolamine (5) (4.33 g, 48.6 mmol). After stirring 30 min, 
diisopropyl azodicarboxylate (DIAD) (11.5 mL, 58.3 mmol) was added slowly via 
syringe. The reaction mixture was stirred an additional 30 min at 0 °C and then 
allowed to warm to room temperature. After 12 h, the solvent was removed by rotary 
evaporation. EtOAc (150 mL) was added to dissolve the residue followed by 
successive washings with saturated aq. NaHC03 (3 X 100 mL), water (50 mL), and 
brine (3 X 100 mL). The organic layer then was dried (Na2S04), filtered, and 
concentrated to -50 mL by rotary evaporation. The organic layer was cooled using 
an ice bath and cold 5% aq. HCI (30 mL) was added. On complete addition, the 
mixture was warmed to room temperature and stirred 20 min. The aqueous layer was 
separated, washed with Et20 several times, cooled to 0 °C, and then made alkaline by 
slowly adding saturated aq. NaHC03. The alkaline aqueous layer was extracted using 
chloroform (3 X 50 mL). The combined organic phase was dried (Na2S04), filtered, 
and the solvent removed by rotary evaporation to afford aminooxy phthalimide 7.1 
(8.53 g, 75%) as a light yellow solid which required no further purification for use in 
120 
the next step; IH NMR (DMSO-d6, 500 MHz) f) 7.82 (d, J= 5.0 Hz, 4H), 4.21 (t, J= 
5.0 Hz, 2H), 2.60 (t, J= 5.0 Hz, 2H), 2.17 (s, 6H); BC NMR (DMSO-d6) f) 163.7, 
135.3, 129.2, 123.8, 76.1,57.4,45.9. 
The phthalimide 7.1 (0.50 g, 2.13 mmol) was placed in a sealed tube and 
iodomethane (6.5 mL) was added. The mixture was degassed using a stream of 
nitrogen and then the tube was sealed and warmed to 50°C. After 2 h, the sealed 
tube was cooled, opened, and the solvent was evaporated (caution: fume hood 
required) to afford the crude ammonium iodide as a light yellow solid; I H NMR 
(DMSO-d6, 500 MHz) f) 7.89 (s, 4H), 4.67 (br s, 2H), 3.8 (t, J = 5.0 Hz, 2H), 3.24 (s, 
9H); J3C NMR (DMSO-d6) f) 164.0, 135.9, 129.4, 124.3, 72.3, 64.2, 54.2. 
The crude iodide salt was dissolved in a mixture of EtOH (5 mL) and H20 
(0.05 mL). Hydrazine monohydrate (1.13 mL, 14.9 mmol) was added and the 
reaction mixture was stirred 4 h at room temperature. The solvents were removed by 
rotary evaporation and acetonitrile (10 mL) was added to the residue. The resultant 
white turbid solution was warmed to 40°C for 10 min and filtered through a cotton 
plug. Filtrate was evaporated and dried under high vacuum to furnish 2.1 (0.41 g, 
78%) as a light yellow amorphous solid: mp 97-99 °C; IR (DRIFT) 3236, 3008, 1480, 
963 cm-I; IH NMR (DMSO-d6, 500 MHz) f) 6.23 (s, 2H), 3.91 (br s, 2H), 3.52 (br s, 
2H), 3.07 (s, 9H); 13C NMR (DMSO-d6) f) 69.3, 64.1, 54.0. HPLC analysis (C18 5~m 
column, gradient elution using 100% H20 to 100% CH3CN over 10 min at a flow rate 
of 1 mLimin) indicated excellent sample homogeneity (98% purity, tr = 1.88 min). 
The elution profile was monitored by UV absorbance at 214 nm. HRMS calculated 
for CSHISN20+ (M+): 119.1179, found: 119.1178. 
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N,N-bis(2-aminooxyethyl)-N,N-dimethylammonium iodide (2.2) 
Using the procedure described for synthesis of2.1, N-methyl-diethanolamine (6) (2.0 
g, 16.8 mmol) was transformed into the corresponding bis-(phthaloyloxyethyl)amine 
8.2 (4.94 g, 72%); IH NMR (DMSO-d6, 500 MHz) {) 7.81 (s, 8H), 4.19 (t, J= 5.0 Hz, 
4H), 2.79 (t, J = 5.0 Hz, 4H), 2.30 (s, 3H); l3e NMR (DMSO-d6 ) {) 164.0, 135.6, 
129.5, 124.1, 76.4, 55.9, 43.0. A portion of this material (0.50 g, 1.22 mmol) then 
was treated with iodomethane in the manner described above to afford the 
corresponding ammonium iodide; IH NMR (DMSO-d6, 500 MHz) {) 7.87 (s, 8H), 
4.71-4.73 (m, 4H), 3.96-3.98 (m, 4H), 3.37 (s, 6H); l3e NMR (DMSO-d6) {) 164.0, 
135.9, 129.4, 124.3, 72.1, 63.3, 52.7. The crude ammonium iodide was treated with 
hydrazine as previously described to give the crude aminooxy product. Purification 
of 2.2 was accomplished by following the same procedure as described for 2.1. 2.2 
was isolated as a light yellow solid (0.23 g, 65% yield): mp 105-107 °e; IR (DRIFT) 
3294, 1469,960,929 em-I; IH NMR (DMSO-d6, 500 MHz) {) 6.24 (s, 4H), 3.92 (br s, 
4H), 3.57 (br s, 4H), 3.08 (s, 6H); l3e NMR (DMSO-d6) {) 69.1, 63.0, 52.3; HRMS 
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N-(2-aminooxyethyl)-N-(2-hydroxyethyl)-N,N-dimethylammonium iodide (2.3) 
In a sealed tube, mono-phthalimide 11.2 (0.60 g, 2.28 mmol) was dissolved in 
iodomethane (10 mL). The reaction mixture was degassed using a stream of N2 
before sealing the tube. The reaction was heated to 50 cc. After 3 h at 50 cC, the 
reaction was cooled and the tube opened. The iodomethane was evaporated (Caution: 
fume hood required) to afford the corresponding ammonium iodide which was used 
in the next step without further purification; IH NMR (DMSO-d6, 500 MHz) [) 7.88 
(s, 4H), 5.29 (br s, IH), 4.67 (br s, 2H), 3.85 (t, J= 5.0 Hz, 4H), 3.56 (br s, 2H), 3.24 
(s, 6H); I3C NMR (DMSO-d6) [) 164.0, 135.9, 129.5, 124.3, 72.2, 67.0, 63.2, 55.9, 
52.6. 
To a solution of the crude ammonium iodide in EtOH (5 mL) at room 
temperature was added hydrazine monohydrate (0.86 mL, 11.3 mmol). After stirring 
12 h at room temperature, the solvents were removed by rotary evaporation. The 
residue was purified using same technique as before to give 2.3 as a white solid (0040 
g, 65%): mp 120-121 °C; IR (DRIFT) 3400, 3238, 1477, 963, 933 ern-I; IH NMR 
(DMSO-d6 , 500 MHz) [) 6.24 (s, 2H), 5.24 (br s, IH), 3.92 (br s, 2H), 3.82 (br s, 2H) 
3.58 (br s, 2H), 3.43 (br s, 2H), 3.09 (s, 6H); \3C NMR (DMSO-d6 ) [) 69.2, 66.7, 63.1, 
55.9,52.4; HRMS: calculated for C6H\7N20/ (~): 149.1285, found: 149.1284. 
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2-(N-methyl-(2-tert-butyldimethylsilyloxyethyl)amino )ethanol (9.1) 
To a solution of diethanolamine (6) (9.0 mL, 78.4 mmol) and Et3N (2.19 mL, 
15.7 mmol) in CH2Cb (300 mL) at 0 °C was added slowly a solution of tert-
butyldimethylchlorosilane (2.35 g, 15.7 mmol) in CH2Cb (150 mL). On complete 
addition, the reaction was allowed to warm to room temperature. After 12 h, the 
reaction mixture was diluted with CH2Cb, transferred to a separatory funnel, and 
washed successively with saturated NaHC03 (3 X 150 mL) and brine (3 X 150 mL). 
The organic layer was dried (Na2S04), filtered and the solvent removed by rotary 
evaporation. The residue was purified by column chromatography (Si02), eluting 
with a 1: 14 mixture of methanol: CH2Cb (product IY 0.43), to afford silyl ether 9.1 
(2.72 g, 75%) as an oil; IH NMR (CDCh, 500 MHz) l) 3.68 (t, J = 5.0 Hz, 2H), 3.55 
(t, J = 5.0 Hz 2H), 2.58-2.59 (m, 4H), 2.31 (s, 3H), 0.85 (s, 9H), 0.02 (s, 6H); I3C 
NMR (CDCh) l) 61.2, 59.3, 58.7, 42.6, 26.0, 18.3, -4.90; HRMS: calcd for 






2-(N-methyl-(2-phthalimidooxyethyl)amino )ethanol (11.2) 
Using the Mitsunobu procedure described above for the synthesis of 2.1, silyl 
ether 9.1 (1.0 g, 4.1 mmol) was transformed into the corresponding mono-
phthalimide product. After work-up, the crude mono-phthalimide was dissolved in 
EtOAc (20 mL) and treated with cold 5% aq. HCI (20 mL). After stirring vigorously 
for 20 min at room temperature, the layers were separated. The aqueous layer then 
was washed with additional portions of E120 (3 x 30 mL), made slightly alkaline by 
addition of saturated aq. NaHC03, and extracted with CHCh (3 x 50 mL). The 
combined chloroform extract was dried (Na2S04) and the solvent was removed by 
rotary evaporation to give 11.2 (0.80 g, 71 %) as an oil; IH NMR (CDCh, 500 MHz) [) 
7.78-7.79 (m, 2H), 7.70-7.72 (m, 2H), 4.28 (t, J = 5.0 Hz, 2H), 3.57 (t, J = 5.0 Hz 
2H), 2.82-2.85 (m, 2H) 2.61-2.63 (m, 2H), 2.32 (s, 3H); I3C NMR (CDCh) [) 163.7, 
134.7, 129.0, 123.7, 76.4,59.3,58.8,55.7,42.2. 
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8or3.2 
Dimethyl-his(2-tetradecylideneaminooxy-ethyl)-ammon-ium iodide (8 or 3.2) 
Ammonium iodide 2.2 (0.05 g, 0.17 mmol) and tetradecanal (0.80 g, 0.39 
mmol) were dissolved in methanol (3 mL) and stirred at room temperature. After 3.5 
h, the solvent was removed by rotary evaporation and the residue was purified by 
column chromatography (Si02), eluting with a 1 :33 mixture of methanol:CH2Ch to 
afford 8 (0.09 g, 82%) as a yellow solid (2.7:1 mixture of (E,E):(E,Z) oxime ether 
diastereomers); TLC (19:1, CH2Ch:MeOH) Rj= 0.45; mp 59-60 °C; IR (neat) 1703 
(C=N), 1467, 968, 920 cm -I; IH NMR (CD30D, 500 MHz) major diastereomer, [) 
7.58 (t, J = 5.0, 2H), 4.53 (m, 4H), 3.83-3.85 (m, 4H), 3.4 (s, 6H), 2.30 (appt q, J = 
5.0 Hz, 4H), 1.58-1.61 (m,4H), 1.37-1.4 (m, 40H), 0.98 (t, J= 5.0 Hz, 3H); BC NMR 
(CD30D) [) 154.9, 67.8, 64.8, 53.2, 33.0, 30.6, 30.3, 27.5, 23.7, 20.1, 14.4; HRMS 
calculated for C34 H70N30 2 +(~): 552.5463, found: 552.5467. 
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Preparation Fe304 nanoparticies (NPs) 
Fe304 nanoparticles (NPs) with an average particle size of 10 nm were 
prepared without any additional stabilizer according to the procedure described by 
Mikhaylova et al. 119 Typically, 5mL of a 0.1 M FeCh and O.2M FeCi) solution were 
added dropwise into 50 mL of 0.1 M NaOH solution under vigorous stirring for 30 
min at room under a N2 atmosphere. The color of the suspension turned black 
immediately. The precipitated particles were collected and removed from the 
solution by applying a magnet (Super Magnetic Plate, Oz Biosciences, France). The 
supernatant solution was removed from the reaction mixture by decantation. The 
isolated NPs were dried using a lyophilizer (55 mg, 94.8% yield). The NPs were 
characterized by TEM, EDX and XRD as described in the following subsections. 
Synthesis of Np·l 
NPs (5 mg) were suspended in methanol (3 mL) and sonicated 5 min at room 
temperature. To the suspension was added N,N-bis-(2-aminooxyethyl)-N,N-
dimethylammonium iodide (2.2, 15 mg). The reaction mixture was first sonicated for 
5 min and then stirred at room temperature. After 12 h, the coated NPs were 
separated magnetically and washed with methanol. The washing procedure was 
performed for total three times and then the coated NPs were dried under high 
vacuum for overnight to obtain Np·l (6.9 mg, 2X104 moleculesINP). 
Synthesis of NP-FITC conjugates 
FITC2 was prepared according to the method described by Trevisiol1 et 
al.214 To an aqueous suspension of Np·l (5 mL, Np·l concentration at 0.8 mg/mL) 
was added FITC2 (15 mg). The mixture was sonicated for 10 min. and then water (5 
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mL) was added. After stirring at room temperature for 12 h, the Np·1· FITC2 
particles were magnetically separated and washed according to the procedure 
described above using methanol. The separated particles then were isolated after 
freeze drying to give Np·l·FITC2 (7.S mg). 
Synthesis of MLP and dMLP 
To Np·l (6.9 mg) suspended in methanol (S mL) was added myristaldehyde 
(20.0 mg, 0.94 mmol). The suspension was stirred at room temperature. After 12 h, 
the lipid-coated nanoparticles were isolated by magnetic sedimentation, washed with 
methanol (2X), and then dried under vacuum S h to yield the magnetic lipid particles 
(MLP; 7.8 mg). 
To NP (S.O mg) suspended in methanol (S mL) was added N,N-dimethyl-
bis(2-tetradecylideneaminooxy-ethyl)ammonium iodide (8; 11.0 mg, 0.016 mmol) 
and mixture was sonicated at room temperature for 2 mins. The suspension was 
stirred 12 h at room temperature. The resultant particles then were isolated by 
magnet-assisted sedimentation, washed with methanol one extra time, and dried under 
vacuum S h to give dMLP (9.25 mg). 
N anoparticle Characterization 
Labeling study 
UV-Visible spectroscopy measurements were taken of NP, NP·l, 
Np·l·FITC2 and FITC2 at concentrations of 0.025 mg/mL. As a control, 
unmodified NPs were mixed with FITC2. 
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TEM, EDX, and XRD measurement of NPs and dMLPs 
Methanol suspensions of NP or dMLP samples were deposited on transmission 
electron microscopy (TEM) Cu grids coated with a carbon film. TEM 
microstructures and energy dispersive X-ray (EDX) spectra then were measured using 
a JEOL JEM 3200FS at 300 kV equipped with an EDX detector. X-Ray diffraction 
(XRD) patterns were obtained using a BRUKER D8 diffractometer with a CuKa 
radiation source (1 Y4 0.15418 nm). The phase identification was performed using 
JCPDS-ICDD 2000 software (The International Centre for Diffraction Data; ICDD). 
TEM, XRD, and EDX measurements of NPs were performed at the Institute 
for Advanced Materials and Renewable Energy, University of Louisville. TEM 
images of dMLPs were taken at the Indiana University (TEM facility). 
Zeta potential measurements 
The zeta potentials of NP, NP·l, MLP, dMLP and derived magnetoplexes 
were measured in water using a ZetaP ALS dynamic light scattering detector 
(Brookhaven Instruments Corporation; Model 90 Plus). The concentration of iron 
oxide in the aqueous particle samples was 0.1 mg/mL. Magnetoplexes were 
formulated at a concentration of 0.5 !-lg pDNA. 
Transfection and cytotoxicity evaluation 
Cell culture 
Human breast cancer cells (MCF-7) were purchased from American Type 
Culture Collection V A, USA. Cells were grown to 50-60% confluency in DMEM and 




Luciferase transfections were performed in triplicate using 0.025 ~g of pDNA 
(pCMV Luc) /well in MCF-7 cells. MCF-7 cells were seeded up to 1 XI05 cells/well 
in a 24-well plate to 50-60% confluence. Magnetoplexes (MLp·pDNA and 
dMLp·pDNA) were prepared at nanoparticle:pDNA ratios of 30, 60, 90, 120, 180, 
360 and 540 by adding the required volume of aqueous suspension of MLP or dMLP 
to a pDNA solution (3 mL, 0.025 ~g DNA/mL). 200 ~L of serum free DMEM then 
was added to each magnetoplex solution followed by incubation for 30 min at room 
temperature. The magnetoplex solutions were diluted to 600 ~L with serum free 
DMEM, and then 200 ~L of the final magnetoplex formulation were added directly to 
each well. For magnetofection, the cell plate was placed on top of a magnetic plate 
(Oz Biosciences) for 1 hat 37.5 °C. After 18 h incubation at 37.5 °C, the cells were 
lysed and luciferase gene expression was quantified using a commercial kit 
(Promega) and luminometer according to the vendor's protocol. Lipofectamine 2000 
(Invitrogen) was used as a positive control. Transfections were also performed in 
similar manner without the assistance of a magnet. 
Cytotoxicity assessment of the dMLP formulations 
Cell cytotoxicity and proliferation of cells treated with dMLP formulations 
were examined by an alamarBlue assay. After transfection of MCF-7 cells using 
dMLP derived magnetoplexes (0.025 ~g of DNA/well) and incubation for 18 h, cell 
viability was measured according to the vendor's (Invitrogen) protocol. Fluorescence 
intensities were measured using a spectrofluorometer (Molecular Devices:Gemini 
EM) by excitation at 540 nm and emission at 600 nm. 
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6.3. Experimental procedures of Chapter 3 
Synthesis 
3.1 
N,N-Dimethyl-N-2-( (dodecylideneamino )oxy)-(2-( (dodecylideneamino) 
oxy)ethyl)ethanaminium iodide (3.1) 
Compound 2.2 (26.5 mg, 0.091 mmol) and dodecanal (35.4 mg, 0.19 mmol) were 
dissolved in MeOH (3 mL) and stirred at RT. After 3.5 h, the solvent was removed in 
vacuo, and the residue was purified by silica column chromatography 
(MeOH:CH2CI2, 3%) to afford oxime ether lipid 3.1 as a white solid (34.6 mg, 61 %; 
(E, E):(E, Z), 5.3:1): RFO.52 (CH2ChlMeOH, 9:1); mp: 155°C (dec); IR (neat): 
1735, 1468, 966, 920 cm"l; IH NMR (400 MHz, CD30D) () (major diastereomer) 
0.86 (t, J=6.8 Hz, 6 H), 1.25-1.45 (m, 28H), 1.43-1.48 (m, 4 H), 2.17 (dd, J=6.8, 7.2 
Hz, 4 H), 3.20 (s, 6 H), 3.73-3.75 (m, 4 H), 4.40-4.41 (m, 4 H), 7.46 ppm (t, J=6.0 
Hz, 2H); \3C NMR (100 MHz, CD30D) () 14.6, 23.9, 27.1, 27.3, 27.7, 30.4, 30.6, 
30.9, 33.2, 53.4, 64.9, 68.0, 68.3, 155.0, 155.5 ppm; HRMS: rn/z [Mt ca1cd for: 
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3.3 
N,N-Dimethyl-N-2-( (dodecylideneamino )oxy)-(2-( (tetradecylideneamino) 
oxy)ethyl)ethanaminium iodide (3.3) 
Compound 2.2 (22.6 mg, 0.078 mmol) and dodecanal (7.2 mg, 0.034 mmol) 
were dissolved in MeOH (1 mL) and stirred at RT. After 14 h, the solvent was 
removed in vacuo, and the residue was purified by Si02 column chromatography 
(MeOH:CH2Ch, 5%) to afford the intermediate mono-oxime ether as a yellow oil 
(14.0 mg, 39 %; (E, E):(E, Z), 1.7:1): R.F0.25 (CH2Ch/MeOH, 9:1). 
The C12 mono-oxime ether intermediate (13.1 mg, 0.029 mmol) and 
tetradecanal (9.1 mg, 0.043 mmol) were dissolved in MeOH (1 mL) and stirred at RT. 
After 14 h, the solvent was removed in vacuo, and the residue was purified by column 
chromatography (Si02; MeOH:CH2Ch, 3%) to afford unsymmetrical lipid 3.3 as a 
yellow oil (13 mg, 69%; E: Z, 2.3:1): R.F0.48; (CH2Ch/MeOH, 9:1); IH NMR (400 
MHz, CD30D) (major diastereomer) [) 0.84 (t, J=6.8 Hz, 6H), 1.23-1.26 (m, 36H), 
1.44 (dd, J=6.8, 7.2 Hz, 4H), 2.15 (dd, 1=6.4,7.2 Hz, 4H), 3.18 (s, 6H), 3.69-3.72 (m, 
4 H), 4.38-4.40 (m, 4 H), 7.44 ppm (t, J=6.2 Hz, 2H); \3C NMR (100 MHz, CD30D) 
[) 14.6,23.9,27.1,27.3,27.6,30.4,30.6,30.7,.30.8, 30.9, 33.2, 53.3,64.9,68.0,68.4, 
155.0, 155.5 ppm; IR (neat): 1728, 1467, 964, 942 cm-I; HRMS: m1z [Mt calcd for: 
C32H66N30t: 524.5150, found: 524.5172. 
132 
3.4 
N,N-Dimethyl-N-2-( « (Z)-octadec-9-en-l-ylidene)amino )oxy)-(2-« «Z)-
octadec-9-en-l-ylidene )amino )oxy)ethyl)ethanaminium iodide (3.4) 
Compound 2.2 (19.7 mg, 0.068 mmol) and cis-9-octadecenal (37.8 mg, 0.142 
mmol) were dissolved in MeOH (3 mL) and stirred at RT. After 3.5 h, the solvent 
was removed in vacuo, and the residue was purified by column chromatography 
(Si02; MeOH:CH2Ch, 3%) to afford oxime ether lipid 3.4 as a yellow oil (45.8 mg, 
90.0%; (E, E):(E, Z), 3.0:1): RrO.51 (CH2ChlMeOH, 9:1); IR (neat) 1730, 1464, 
964, 942 cm-I; IH NMR (400 MHz, CD30D): (major diastereomer) b 0.84 (t, J=6.8 
Hz, 6H), 1.23-1.27 (m, 40H), 1.42-1.47 (m, 4H), 1.96-1.97 (m, 8 H), 2.15 (dd, 
J=6.4, 7.2 Hz, 4H), 3.16 (s, 6 H), 3.68-3.71 (m, 4 H), 4.38-4.39 (m, 4 H), 5.27-5.29 
(m, 4H), 7.43 ppm (t, J=6.0 Hz, 2H); l3C NMR (100 MHz, CD30D) b 14.6, 23.9, 
27.6, 28.3, 30.4, 30.5, 30.6, 30.8, 31.0, 33.2, 53.3, 64.9, 68.0, 130.9, 131.1, 155.0 
ppm; HRMS: m/z [Mt: calcd for C42H82N30/: 660.6401, found: 660.6395. 
Zeta potential and Iiposome size measurements 
Measurements of liposome size, lipoplex zeta potential and formulated 
nanoparticle size were performed using a ZetaP ALS dynamic light scattering detector 
(Brookhaven Instruments Corporation; Model 90 Plus). All measurements were 
taken in water. Lipoplexes were formulated at a final concentration of 0.1 mg oxime 
ether lipid per mL water. To formulate lipoplexes at different N:P ratios, 100 mL of 
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the liposome formulation was added to the required quantity of pDNA (taken from a 
stock solution of 0.1 mg pDNA per mL) in an Eppendorftube. After incubating each 
lipoplex for 15 min, the solutions were diluted to 1 mL by adding ultra-pure water. 
Measurements were taken within minutes of formulation. 
Liposome formulation 
An equimolar amount of DOPE from a stock solution (10 mg DOPE per mL 
CHCh) was added to a solution of oxime ether lipid (1 mg) in CHCh (0.20 mL). The 
solvent was evaporated, and the resultant thin lipid film was dried under vacuum (4 
h). Ultra-pure water (3 mL) was added to the dry lipid film, and the suspension was 
sonicated (bath sonicator, Laboratory Supplies Co., Inc., Ithica, NY) for 1 min at RT 
to furnish the liposome formulation (0.33 mg oxime ether lipid I mL). 
Tissue Culture 
Human breast cancer cells (MCF-7) and lung tumor cells (H1792) were 
purchased from American Type Culture Collection (Manassas, V A, USA). Cells were 
grown to 50-60% contluency prior to transfection. MCF-7 cells were cultured in 
Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA), 1 % 
pennstrep (Mediatech Inc., Manassas, VA, USA, 10% fetal bovine serum (FBS; 
Valley Biomedical, Winchester, VA, USA). H1792 cells were cultured in RPMI 
(Invitrogen), 1% pennstrep (Mediatech Inc.), 10%FBS. 
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Transfection and cytotoxicity studies 
Luciferase assay 
Luciferase transfections in MCF-7 and H1792 cells were performed in 
triplicate using 0.025 mg of pDNA (pCMVLuc) per well. Cells were seeded up to 
lX105 cells per well in a 24-well plate to give 50-60% confluency, and 400 mL of 
media containing 10% FBS was added to each well. Lipoplexes (lipidepDNA 
complex) were prepared at N:P charge ratios of 3, 5 and 7 by adding the required 
volume of liposome solution to a pDNA solution (3 mL, 0.025 mg DNA per mL) and 
incubated for 5 min. Serum free DMEM (100 ilL) was then added to each lipoplex 
solution followed by incubation for 20 min at RT with occasional gentle vortex 
mixing. The lipoplex solutions were diluted to 600 ilL with serum free DMEM, and 
then an aliquot of the final lipoplex formulation (200 ilL) was added directly to each 
well. No additional media containing FBS was added to the cells during transfection. 
After 18 h incubation at 37.5 DC, the cells were lysed and luciferase expression was 
quantified using a commercial kit (Promega Corp., Wisconsin, USA) and 
luminometer according to the vendor's protocol. Lipofectamine 2000 (Invitrogen) 
and jetPrime (Polyplus Transfection, SA, Illkirch, France) lipoplexes were prepared 
at the vendor recommended stoichiometry (2 ilL stock per mg DNA). 
Luciferase transfections were also performed in duplicate using 1 Ilg of pDNA 
(pCMV-Luc)/well in MCF-7 cells as described above. Cells were seeded up to 4x105 
cells/well in a 6-well plate to give 50-60% confluence. Transfection activity of lipid 3 
was evaluated at N:P=7. RLU/llg of protein was measured using the BCA protein 
assay kit (Bio-Rad, USA). 
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GFP expression 
Transfection studies were performed using a GFP reporter gene in MCF-7 
cells using 0.1 mg of pEGFP DNA (Clontech Laboratories Inc. WI, USA) per well in 
a 24-well plate with a similar transfection protocol as described for the luciferase 
assays. Cells were examined 40 h post transfection by fluorescence microscopy 
(EVQS, Advanced Microscopy Group, Bothell, WA, USA) and photographed. 
Cytotoxicity evaluation 
Lipid cytotoxicity was evaluated using the vital dye trypan blue to distinguish 
between live and dead cells. MCF-7 and H1792 cells were seeded at 1X104 cells per 
well and then grown to 50-60% confluency in 96-well plates. Transfections were 
performed as described above. The media was removed 18 h post transfection. Cells 
were then trypsinized by adding 100 I-tL trypsin to each well and incubated for 5 min 
at 37.5 °C. Trypsin was neutralized by adding IX phosphate-buffered saline (IX 
PBS), and then 10 I-tL of extract from each well was mixed with 10 I-tL of try pan blue. 
Dead and live cells were counted under an inverted microscope to determine the 
percentage cell viability using a hemocytometer. 
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6.4. Experimental procedures of Chapter 4 
Synthesis 
- OH 
o OH N,o~~f 
OMeO 




2-« (E)-(l-( (2R,4S)-4-( «2R,4S,SS,6S)-4-amino-S-hydroxy-6-methyltetrahydro-
2H-pyran-2-yl)oxy)-2,S,12-trihydroxy-7 -methoxy-6,1I-dioxo-l,2,3,4,6,11-
hexahydrotetracen-2-yl)-2-hydroxyethylidene)amino)oxy)-N-(2-hydroxyethyl)-
N,N-dimethylethanaminium iodide (Dox-AO) 
To a solution of Dox-HCI (Selleck Chemicals, Houston, TX, USA; 45.0 mg, 
0.077 mmol) in anhydrous methanol (35 mL) at room temperature was added N-(2-
hydroxyethyl)-N,N-dimethyl-2-aminooxyethylamrnonium iodide (2.3, 100 mg, 0.38 
mmol) and trifluoroacetic acid (0.5 mL). After stirring the reaction mixture at room 
temperature for 96 h, the solvent was removed under reduced pressure. Acetonitrile 
(5 mL) was added to the residue and the suspension was sonicated 1 min at room 
temperature and then warmed to 40 DC for 5 min. The suspension was then cooled to 
-20 DC. After storing 18 h at -20 DC, the supernatant was decanted and the remaining 
precipitate (red solid) was dried under reduced pressure to afford Dox-AO (55 mg, 
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91%): mp: 50-53°C (dec); IH NMR (700 MHz, CD30D) {) 1.296-1.33 (m, 3 H), 1.92 
(dd, J=8.40, 4.20 Hz IH), 2.05 (dd, J=7.7, 3.5 Hz, IH), 2.42 (dd, J=8.4, 6.3 Hz, IH), 
2.57 (d, J=I1.2 Hz), 3.15 (d, J=14 Hz, 2H), 3.22-3.32 (m, 10H), 3.36-3.62 (m, 2H), 
3.63 (s, IH), 3.72-3-3.86 (m, 3H), 4.03 (d, J=21 Hz, 6H), 4.29-4.30 (m, 2H), 4.51-
4.61 (m, 4H), 4.87-5.04 (m, IH), 5.48 (s, IH), 7.55 (d, J=8.4 Hz, 2H), 7.81 (t, J=7 
Hz, 2H), 7.89 (d, J=7.7 Hz, 2H); l3C NMR (150 MHz, CD30D) {) 15.7,28.0, 33.09, 
38.1,47.2,47.3,47.4,47.6, 51.8, 54.2, 55.4, 55.8, 63.0, 63.7, 66.4, 66.6, 67.6, 68.5, 
71.4, 71.9, 99.6, 110.7, 110.9, 118.9, 119.0, 120.1, 134.9, 135.0, 135.1, 135.9, 154.8, 
156.1, 161.0, 162.6, 186,4, 186.8 ppm; HRMS: calculated for: C331-44N3012+ (Mt, 
674.2920; found: 674.2926. 
Preparation of sNp· AO· Dox 
A suspension of Fe304 nanoparticles (5.5 mg) in methanol (1.5 mL) at room 
temperature was sonicated (1 min) followed by addition of a solution of N-(2-
hydroxyethyl)-N,N-dimethyl-2-aminooxyethylammonium iodide (2.3) (30 mg) in 
methanol (1.5 mL). The reaction suspension was sonicated (1 min) at room 
temperature and then stirred 12 h. The resultant Np·AO particles were magnetically 
sedimented to facilitate removal of the supernatant. The particles then were washed 
with methanol (1 mL,2x). The washed particles were dried under reduced pressure 
to afford Np·AO (7.42 mg). 
A suspension of Np·AO (7.4 mg) in anhydrous DMSO (1.5 mL) at room 
temperature was sonicated (1 min). Within 1 min of sonication, a solution of 
doxorubicin-HCI (10 mg) in anhydrous DMSO (1.5 mL) was added. The reaction 
suspension then was sonicated (1 min) at room temperature and stirred at room 
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temperature an additional 12 h. The resultant drug-conjugated particles were 
magnetically sedimented to facilitate removal of the supernatant. The particles then 
were washed with DMSO (1.5 mL, Ix). The supernatant was collected and 
centrifuged for 10 min at 4 0c. The pelleted and magnetically separated partcicles 
were combined and dried under reduced pressure to afford sNp·AO·Dox (9 mg). 
Synthesis of dNp·AO·Dox 
Fe304 nanoparticles (NP, 7 mg) were suspended in anhydrous DMSO (1.5 
mL) at room temperature and sonicated (1 min, room temperature) using an Ultra 
Sonicator water bath. To the resultant NP suspension, a solution of Dox·AO (20 mg) 
in anhydrous DMSO (1.5 mL) was added. The reaction suspension was further 
sonicated for 1 min at room temperature and then stirred 12 h. The resultant drug-
loaded particles were purified as described above to afford dNp·AO·Dox (9.4 mg). 
Synthesis of Np·Dox 
A suspension of Fe304 nanoparticles (9.0 mg) in anhydrous DMSO (1.5 mL) 
at room temperature was sonicated (1 min) followed by addition of a solution of 
Dox·HCI (20 mg) in anhydrous DMSO (1.5 mL). This reaction suspension was 
sonicated (1 min) and then stirred at room temperature for 12h. The loaded particles 
were isolated using the magnetic separation and washing procedure described above 
to furnish NP·Dox (10 mg). 
NP characterization 
Transmission electron micrograph of dNp·AO·Dox 
Methanol suspensions of dNp·AO·Dox samples were deposited on 
transmission electron microscopy (TEM) Cu grids coated with a carbon film. TEM 
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microstructures and energy dispersive X-ray (EDX) spectra then were measured using 
a JEOL JEM 3200FS at 300 kV equipped with an EDX detector. TEM measurements 
were performed at the Indiana University (Bloomington), TEM facility. 
Dox-AO loading calculation 
Volume of 1 mg NP = mass/density = 0.001 (g)/5.24 gcm-3 = 0.0002 cm3 (V) 
Volume of one NP = 4/3 1tf3 = 5.23XlO-19 cm3 (VI) 
Number ofNPs in 1 mg = V/ VI = 3.82X1014 (X) 
0.37 ~mol Dox-AO is attached! mg NP 
Number of Dox-AO molecules in 0.37 ~mol = 2.22XlO17 (XI) 
So, number of Dox-AO molecules attached to each NP = Xt/X = 580 
Surface area of a single NP = 4 1t~ = 31428.57 A 2 (A) 
Polar surface area (PSA) of 4.1 = 21 A2 (PSA was calculated using a software form 
http://www.daylight.com/meetings/ emugOO/Ertlltpsa.html) 
So, maximum number of Dox-AO molecules that can attach on surface side by side 
of each NP or footprint of Dox-AO = NPSA = 1450 
Zeta potential measurements 
The zeta potentials of NP, sNP-AO-Dox, sNP-AO-Dox, NP-Dox were 
measured in IX PBS using a ZetaPALS dynamic light scattering detector 
(Brookhaven Instruments Corporation; Model 90 Plus). The concentration of each of 
the sample was 0.3 mg NP/mL buffer. 
AMF -induced NP heating 
A suspension of dNP-AO-Dox (2.5 mg) in PBS (1 mL) was exposed to a 
continuous AMF (EASYHEA T'M 8310LI solid state induction power supply, 
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Ameritherm, Inc., 5 turn coil with ID: 5.0 cm and OD: 6.5 cm, 203 kHz, 350 A) for 
18 min. The AMF exposure was started after the temperature of the suspension had 
reached 37.0 °C. The temperature of the suspension was measured every 3 min using 
an optical fiber temperature probe (Neoptix Inc., Quebec, Canada). 
Solution containing AMF-triggered drug was analyzed by HRMS. The 
supernatant was collected after AMF exposure and diluted to 0.5 !!mol for analysis 
using a FT-ICR-MS (Fourier Transform Ion Cyclotron Resonance Mass 
Spectrometry ). 
Drug release studies 
AMF -induced drug release 
The drug-loaded nanoparticle formulation were suspended in PBS by 
sonication (1 min) and then subjected to AMF-exposoure (203 KHz) for 18 min. 
Every 3 min, a 10 !!L of aliquot was taken out and diluted to 1 mL for UV 
measurements at 480 nm.86, The concentration of drug released was calculated using 
Beer-Lambert's law. Release study was performed in triplicate. 
According to Beer Lambert's law: A = dc 
Where, A is the absorbance; £ is the molar absorptivity (a constant); I is path length (1 
cm). Thus, if the path length and the molar absorptivity are known and the absorbance 
is measured, the concentration of the substance or 'c' can be deduced. 
Drug release study at 37.5 °c 
dNp·AO·Dox (3 mg NP/mL in PBS) was incubated at 37.5 °C for 18 min. 
Drug release study was conducted in similar fashion as stated above. 
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AMF -induced drug cytotoxicity in MCF -7 cells 
Human breast cancer cells (MCF-7) were purchased from American Type 
Culture Collection (VA, USA). Cells were plated in 30 mm dishes at -4X105 
cells/dish, and then grown up to 50-60% confluency in DMEM, 1 % Pennstrep 
(Mediatech, Inc, VA) and 10% FBS (Valley Biomedical, Winchester, VA). 
Stock solutions of the nanopartic1e formulations NP·AO, dNP·AO·Dox, 
sNP·AO·Dox, and NP·Dox, were prepared in PBS IX buffer solution at a uniform 
Fe304 concentration of 1 mg/mL. To the MCF-7 cells maintained at 37.5 DC were 
added specific doses (0.1, 0.25 mg or 0.5 mg) of the NP formulations. The required 
volume of NP formulation was first diluted to 2 mL in DMEM containing 10% FBS. 
The media was removed and NP formulations were added to the cells. After 1 h of 
incubation with NP formulation at 37 DC, cells were exposed to a continuous AMF 
for 15 min using same parameters as described above. Dox·HCI (0.5 !-lmol) and 
Dox·AO (0.5 !-lmol) served as positive controls. Untreated (no NP formulation 
added) cells were also exposed to an AMF. Cells were also treated with NP 
formulations but not exposed to an AMF; these served as another control group for 
the experiment. After AMF exposure, the cells were incubated at 37.5 DC for 48 h. 
The media was then removed and the cells were trypsinized by adding 500 !-lL trypsin 
to each well and incubated for 5 min at 37.5 DC. Trypsin was neutralized by DMEM 
containing 10% FBS, and then 10 !-lL of extract from each well was mixed with 10 
!-lL of trypan blue. Dead and live cells were counted under an inverted microscope to 
determine the percentage cell viability using a hemocytometer. 
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Fluorescence imaging of MCF-7 cells 
A cytotoxicity experiment was performed exactly as described above on 
MCF -cells using the NP drug formulations. After 6 h of treatment media was 
removed and 1 ml of IX-PBS was added to each dish. Then fluorescence images of 
cells were taken using a fluorescence microscopy (ex/em: 480/590 nm, EVOS, 
Advance Microscopy Group, W A). 
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Figure A.L Microscope images of MCF -7 cells after 48 h of treatment with Dox and 
Dox·AO . A. Untreated cells. B. Dox·HCl treatment. C. Cells treated with Dox·AO. 
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Figure A.3. EDX sptectrum ofNPs. 
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15 20 
Figure B.4. TEM micrograph of dNp· AO· Dox particles; inset is a single particle. 
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Nucleophilic cationization reagents 
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Nurloqitilic atioriution reapnts fk1rd with ominooxy groups an! describl!d. I'ra<tfcal synthesrs ci 
mono- and bis-arrinooxy tolTa..Ikylammanium iodid!s indJding N-h~mcyahyl.functionalilled analogs 
ar"repoltl!Ci An oximation .,.omp!! usill! on" lith" ~agents is pr4!S4!nt4!d to illustr.lt"thtir US" in syn-
thl!Sis ci cationic matHials. 
A wide V.1fiety Ii materials have been modllied by the covalent 
.1tuchment of quaternary .1mmonlum fullCtlonallly to furnish 
derlvatlves with overall positive c:harge.
' 
This proce;s, a derlvatlza-
tlon known as catlon~t1on. typical Iy procted$ via reaction of the 
substra~ with an electrophlllc reagent oontllnlng.1 quaternary 
ammonium salt Fa: eumple. the catloniLltion of prold1l$ ls per-
formed toenllance their lntracdlul.tr deUvery via adsorptJv~med­
lated endocytosis. 2 The catIonizatlon cl cellulose fibers (e~ 
cotton) can Improve the upuk:e of dyes In subsequent coIa:lng 
operations. 3 These applications and others principally reJy on catl-
oniLltlon re.1ll'!nts of the type 1- 5 depicted In Figure 1. Indeed. 
chiorohydrln ' · .tnd epoxide re.1ll'!nts 25 and 3" holve been partie-
uLtrly useful for the cationiLltion of wboh)'drate domalns In reolC-
tIons with bases at elevated temperatures. The reagents 47 and S-
I Dustrate other permutations cl reactive electrophiOc groups used 
In reactions to derlvatlze materLtls with ammoolum salts. 
Of particuLtr Interest 10 us" ls the use cl quaternary ammonium 
salts attached to lipid- a: polymer-frameworks as vehicles for the 
IntraceDuI.1r delivery of polynucleotldes to mammalLtn ceJls.'· 
We felt that a mlk\, more convenient procedure for direct attach-
ment of .1mmonlum Ions to substrates v.ouJd greatly Improve 
our .1bDltles toacress 11M cationic materials. On considering alter-
native Slrateg:ies. the chernospedlic reaction between amlnooxy 
and kttone or .1ldehyde carbonyl groups appeared to be an ldea~ 
nucleophlOc counterp.ut to current method$.' 1 Given the ease of 
oxlrnatlon and the rd>ust nature of the CIlClrne ether linage. we 
targeted amlnooxy re.1ll'!nts 6.1 and 6.2 (FI~ 2) fo r synthesis. OUr 
Interest In gene transfer ma~rl.als also led us to prep.tre hydroxy-
ethyl· funct\onallz.ed an.1\ogs 7.' and 7.2. Thebenefitofh)<dracy~ 
thylated pow domains In gene delivery Is ~II documented. 12 
Consequently, we disclose herein a genera l synthesis of the novel 
nucleophilic catlonlzatlon re.1gents 6 and 7. 
• CDtRSp<II4l11uhar. Toi~ <1502 1152 1IIIi!I: lllC . 1502 85Z 7214. 
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Reaction of the commercially available ethanoLtmlnes &. 1 .lnd 
8.2 (Scheme 1 )wlth N-hydroxyptholllmide (NHP) under Mltsunobu 
6.1 
I 8 I b. c (78%) 
"""",N - . ,_"",,- . N - a HO 'R PntU ~ ' R 6.2 
(65%) 
8.1:R=OH3 O.1: R =OH3(75'l1i) 
1.2:R =CH2Cfi20H 1.2: R= CH2Cfi20PhI (~) 
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fUnc:tiDlIllization of ron axide IIln~de:s with ~ nmonilm ion-bued aminOOltY <U1d 
axirneethefSubstr~ provIdes~ IItxibie IOltefar ner~tinlllli1Jl1t1lc~eddmyverlO".Usirc the 
MCF-7 brustall,:l!fcrllline,wrfinclnJS $/tow that pO/lll\ f'NII1r!IDpI~deriwd fiorn the lipid-coated 
~de rorrnula.tion dMLP I11llUl'ea In me plt!$tllte of lOS smun with or wimout RU&naic 
usUtante t slIrillcandy hiJher levels man .. ammonly II$ed ationic Ilposome forrllJlatian, bad on 
uclerue lISSi)l. The present ion~iril" dlc:lc chemistry .tPProach fumi.shes reA n.nopal1klts with 





I . Inrroducdon 
Since the mlna! report by Mah's group on the useot m~dc 
n.1llopartlcles to enh.mce v\raJ...m~tfXI transduc:tlon III. much 
rese.uch effort has been dlreClrd toward the development d nano-
slud RUgJletlc vectors fot Intt~lIUW'deUvery or polynudeotldes 
(21. Indeed, the rising ntere In 'lNgnetoli!ct!on'. the ~rm mlnfXI 
by Scherer etaL(31 to denote magnet sistfXI ~ne delivery [4.51. 
has IfXI toa plethora of new trategles for funct\on.tlill .magnetlc 
particles to ptomo~ assocImon with neptJvely dlarged 011 onu-
deotlde$ [6L DNA or siRNA (71. The m*dty of apprG.llches have 
relied on co.Kl Iron oxide n.tnopartlcles Of O.1IIOCDroposl s with 
atlo polymer$. such as pol}"4.~Iy$lne 181 or. In p~ttlcuLu po 
et!\ylen mine (pa) I 11 ~ The high poslti¥e cha~ (121 of PEl 
eff«tl ely promo~s DNA transfer InlO cells. AddItIon.tlly. the 
polyamine b.lckbone of pa enhances esape of DNA co~lexes 
entrapped within endosomes by me d a prolOn po e effect 
that: incrt.lses osmotic pressure ~nd causes endosome rupture 1131. 
M~gnetlc PEJ..cN~d n.1llopartJcles ~nerilly pre:parfXI by 
mixing suspensions of m nedte (FoOt) nanocrysui.s with sotu-
tIons of linear or bf.1llched PEl (141. More recently. ;an In sltu 
pre:pa~lon IISI InwIvIng predpl~n of Lton CIt/de In Ihe pres-
ence of PEl ~nd ~ method for covalent attachment (161 of PEl to 
chltosan-coated Iron 0 Ide O.1IIopardcles have been de bed 
Elaboration of PEj..<n.l~d lton oxIde nanopartlcles. such as by 
a II1II«. ~l! 1 SOl 1152 ICIi!J.. 
ftC: mk:bIoLaana.... (MJf. HIIIID). 
0l4208612/S - fmnr INIU!r 02011 Ekev1!r lid. All 11"," ",.rwd. 
daI :1QJO~ IUOlO.l2JIC1 
addition of atlon peptide fragments (171 0 single chain anti-
bodies 1181. ls also.In .tee. under Intense In...estlgatlon.lrrespectlve 
of the mode of genentlon or Subsequent funcdonaJludon. 
magnedc PEkoatfXIlron CIOde n.tnovectors readily ClImb ne with 
polyoocleotlde$ on Imple mixing to ~nerate the correspond! 
m~dc electrostatic cha~-.llftnlty oo~lexes. The te:sul 
'magnetoplexes' (nomenclature derived by extrapolation of Ihe 
established ~rm magner:oliposome (191 ~nd the terms Iipoplex .. nd 
polyplex [20D have beenusedprl palJy for gene delivery n tro; 
ha.ve...er. successful RUgJlaofe<tlon also h.lS been demonstratfXI n 
~IW) by ex~1'N11y applying a m netic gradient to the treatment 
area. for t!lWIlple (211. 
One concern that plagues appliatlons Inwlvlng PH Ihe 
~ssoc\ated cellular tCltlcity. The high positive char~ den ty of PEl 
disrupts u1ar merrbranes (221: thus, complications a ng ftom 
vector toxicity alllict many PEl-based gene Ihmpy approaches 
1231. To overcome th limitation, ~ teO!nt focus I the l'ield of 
~netorectlon has been to de...elop IJpicI-ba d magnecoplexes. 
This strategy has been realized In part by mild preformed II 
oplexes (C.ttIonic I pld:helper Iipld:ONA)wlth m netill! (241 or by 
.adding tr.ans fe(tlon-actlve a lion Ic llposome for mulations (C.ttIonlc 
IIpld:helper lipid) to either oleic ackk:oatfXI l25261 or dextr.a,.. 
coatfXI l271 mapetlte prior to complexation with nucleic adds to 
form ma,gnetoplexes. 
Given thOlt the molecular structure d atlonlc lpid.s his 
.I prdound Inlluence on ~ne delivery (28). Itls surprlsl 1h0lt bY 
m nelOfectlon srudles have exploited struClUre-actMty optlmj.. 




Hydrophobic Oxime Ethers : A Versatile Class of pONA and 
siRNA Transfection Lipids 
Souvik Biswas}a] Ralph J. Knipp/a] Laura E. Gordon/b] Seshagiri R. Nandula,lcJ Sven-Ulrik Gorr,[e) 
Geoffrey J. Clark,iJl] and Michael H. Nantz*la] 
The manipulation of the cationic lipid structures to lnaease 
polynucleotide binding and delvery properties. wille also min-
inlzlng assod.eeI cytotollid~ has been a principal Slrategy 
for developing next-generation transfection agents. The polar 
(DNA binding) and hydrophobic domai15 of transfecdon Ipids 
have been extensiYely stucled; howeYer, the linking domain 
comprising the substructuJe used to tether the polar and hy-
dIophobic domains has attracted considerably less attention as 
an opd milatIon variable. Here. we examine the use of an 
olIime ether as the Inking domain. Hydrophobic olIime ethers 
Wl!Je rNdIy assembled via dick chemistry by ollimatlon of hy-
Introduction 
Cationic lipids and their derived liposomes have become the 
most well-studied and widely used synthetic. nonviral gene de-
livery vehicles since Feigner et al lli first disclosed DOTMA-
mediated gene transfer in 1987.12.1I Due to the major fimita-
tions of viral vectors, such as associated Immune responses, 
limited polynucleotide carrying capacity and high cost.lI.~ cat-
ionic fipids remain an attractive alternative. The advantages of 
low Immunogenicity. the ability to transfect RNA or DNA of 
nearly unlimited size.'" '' and the relative ease of cationic lipid-
plasmid DNA (pDNA) or RNA complex (lipoplex) formulation- ] 
continue to attract interest aimed at developing saler and 
more efficient cationic lipids for use as transfection agents.1I1 
Cationic lipid molecules. such as the prototypical dual chain 
lipids DOTMA" ] and OOTAplO1 (Figure I). contain a polar. posi-
tively charged (DNA binding) head group connected to a hy-
drophobic domain via a linking functionality. These three prin-
cipal structural components of cationic glycerol-type lipids 
polar 
domain linker hydrophobic domain 
ether DOTMA 
fig .... 1. Struetl.nl cIomains of oommon transfe<:tion lipids. 
drophoblc aldehydes using an amInooxy salt. A facie IgatJon 
reaction delivered the desked compounds with hydrophobic 
domain asymrneuy. umg the MCf-7 breast cancer. H1792 
lung cancer and PAR C 10 salivary epI1helal eel Illes. our find. 
Ings show that IpopIell!5 derived from oxime ether lipids 
transfect In the presence of serum at higher levels than c0m-
monly used lposome formulations. based on both Iuclerase 
and green fluorescent protein (GFP) assays. GIven the bIoI~ 
cal mmpatiblity of ollime ethers and their ease of fonnation. 
this func1IonaI group should tlnd significant applcatlon as a 
Inking domain In future designs of transfectlon vectors. 
have been extensively studied in efforts to improve lipid-medi-
ated intraceHuiar delivery of polynucleotides to mammalian 
cells.I" 1 Many structure-activity relationships have been deter-
mined. >. Ill particularly for the hydrophobic domain. Indeed. 
the hydrophobic domain's structural variables of chain length. 
degree of unsaturation. and domain asymmetry are among the 
strongest contributors to transfection efficaCY, 4 Fewer direct 
structural comparisons of changes in the cationic lipid back-
bone. or linking domain. have been reported. with the most 
weU-Itnown comparison being that of the diether DOTMA 
versus the diester DOTAP.o" The linking functionality. and to a 
lesser extent the cationic head group. seem to be the prinCipal 
determinants of toxicity. H71 The linker determines conforma-
tional flexibility. degree of stabiUt)4 and biodegradability. 
Among the most studied chemical functionalities comprising 
the linking domain of transfection fipids are the ether. ester. 
ortho ester,' ..... 1 carbamate. I amide."ll'l and phosphonol2~ 
moieties. 
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1320 S. Brook Street. Louisv;'" KrntucJcy 4(JZ91 (USA) 
form': mldroelJIIJntlfllooisvilludu 
lbl L E. Gordon. Dr. G.J. Oorlc 
School of Medidne. Brown ConCtr Cent ... University of Louisville 
519 S. Jackson Strtl!t. Louisville. KtrIrucky 4(}191 (USA) 
leI Dr. S. R. NandJa, Dr. S.·U Gorr 
School of Den lis tty, IkINersity of Minnesota, Moos Health ScifflCes Tower 
SIS Dt/awOf' SlTtI!t Sf; Mimtopols. Minnesolrl 55455 (USA) 
~ Supporting infamation for this ride is ..... Uable on the WWW under 
http://dx.dolorgl1o.1002lcmclc.201100159. 





Cite this: Analyst, 2011, 136, 4662 
www.rsc.orglanalyst 
Dynamic Article Links 0 
COMMUNICATION 
A novel microreactor approach for analysis of ketones and aldehydes in breath 
Xiao-An Fu, *11 Millgxiao L~a ouvik Biswas/ Michael H. Nalltzb iUld Richard M. Higdshibcd 
Rt!rei.ed 1911r July lOll, Accepled 1911r AuguSI101 J 
001: IO.I039/c1anl56ISg 
We report a fabricated microreactor with thousaols of micJ'opilars 
in channels. Each micropillar surface is chemically functiooalized 10 
selecti~e1y precoocentrate gaseous ketones and aldehydes of exhaled 
breatb and to enbanre ultra-trace, rapid analysis by direct-infusioo 
Foorier transform-ioo cyclotron reliOllWlCe (FT-ICR) mas spec.-
trometry (MS). The mlcropillar reactive coating contains the 
quaternary 3mmoniwn amioooxy salt 2-(amioooxy)ethyJ- ,N,N-
trimethyl3JUlllOlli1Dll iodide (ATM) fc. capturmg trace carbon)i 
VOCs by means of 30 oximatioo reaction. We demonstrnle the 
utility of this approach for detection of C. to CIl aldehydes and 
ketones io exhaled breath, but the approach i awicable to any 
gaseous sample. 
Aoalysis of exhaled breath has been elevated to an international 
research frontier because of its potential and applicabitity in nonin-
vasive reaJth diagnosis, metabolite bioinformata, and drug 
discovery .... The gISCOOS portion of breath is a oomplex mixture of 
atmospheric gases, water vapor. and trace volat~e ol"!1ilnic 
compounds (V0Cs). In 1m, Pauling reported the first ~ro­
matographi.: analysis of !reath, and the study revealcxl the preserx:e 
of a larg: number of VOCs in human !reath.' A nIDDber of recent 
pUbtications suggest that the analysis of exhaled breath promises to 
be a non-invasive diagnosis for early detection of particulate cancers 
since some VOCs in exbaIcxI breath represent metaboli.: output of 
cancer tissues and ceOs.'-u 
There are se\\:ra1 criticaJ challenges for the analysis of VOCS in 
exhaled breath, including u1tra-trace concentrations of VOCs and 
interference of complex gas mixtures. Exhaled breath contains more 
than 200 VOCS. Recently, several reports indimte that some ketones 
and aldehydes in exhaled b-eath coukJ be used for the diagnosis of 
IWJg cancer in its early stag: ..... ' .... u 
However, so far there is no estabtished protocol for the analysis of aD 
ketones or akJehydes in exbaJod breath. in part due to their highly 
reactl\\: nature. These carbonyl metabolites are produccxl in 
biochemical pathways as intermediates and some can be WJique to 
"Department of o,emiCQ! Engintrring, University of Louisville, Louisville, 
K y, «J208, USA. E-maiL' xiooon.fit@1ollivU!udu 
'Department of Chemistry. Uni~rsity of LouisvUIe, LouisviJl~ KY, «J292, 
USA 
<Cemer for Regulatory and Environmental Analytical MetaiJolomic;s 
( CREAM), University of LorosviUc, LOllisvin •• KY. 40208. USA 
'Jomes Graham Brown ClIneer Centtr. Uni~rsity of Lorosl'ilJe, Lord.rville, 
KY, «J292 
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a given pathway or process. However. e\'en common carbonyl 
metabolites can be attributed to specific processes when stable isotope 
labeled substrates are metabolized (e.g. by hIDDan subjeas) and 
detected by mass spectrometry or NMR.'4,U Volatile ketones and 
aldehydes are also genemted from damaging oxidatiyc reactions, such 
as lipid peroxidation.' .... Thcrcfore, developnent ofa new method for 
analysis of ketone and akJehyde VOO in exhaled breath is a (J1lcial 
first step to fulfilling the potential that breath analysis promises. 
Ketones and aldehydes can be detected by proton transfer reaction 
mass spedromctry (PfR-MS), ....... or selected ion ftow tube mass 
spectrometry (SlFT-MS) without any preconcentration process.2WS 
Most recently. solid phase mi.:roextractlon (SPME) with adsorbed 
0-2.3,4,s.6-(pentalluorobenzyl)bydroxylamine hydrochloride 
(PFBHA) has been used for analysis of akJehydes in exhaled breath 
by gas cbromatography-mass spedrometry (GC-MS).· .. SPME is 
a popular preconcentration method introdwed a decade ago as 
a mpid extraction technique for analysis of volatile compoWJds from 
a variety of matrioes?~ However, tbe surface area of the SPME 
polymer extractlon phase is smaD and akJehyde capture requires 
physical adsorpt.ion of PFBHA onto SPME first. In most cases, it is 
also extremely difficult to improve upon, or even determine the 
volIDDe of air that is actuaDy samploo by the SPME fiber. The quality 
of the fibers depends on the manufacturer, and the perfonnance 
varies from batch to batch. Derivatilation of ketones and akJehydes 
by reactlon with 2,4-dinilrophenylb)drazine has aro been used for 
analysis of carbonyl compounds in exhaled breath, ..." which has the 
advantage of converting volatile aldehydes and ketones into stable, 
easy.to-bandle non-volaille anaIytes. Howe\I:l", this dass of reagents 
was not designed to aid in detection by modern ultra-sensitive MS ion 
sources such as nanoelectroopray. 
In this work, we deuibe a muoreactor approach for chemo-
selective capture of ~us ketones and akJehydes from gaseous 
samples uch as exhaled breath. The microreactor was fabricated on 
a ~icon wafer and charged with an aminooxy-/imctlonalized 
quaternary ammonium sail The high selectivity of the aminooxy 
moiety (R-ONHz) for reaction with ketone and aldeh)de carbonyl 
groups suggested tbat an oximation reaction coukJ be used to seJec-
ti'!:ly capture ketone and aldehyde metabolites dirertly from the air. 
such as exhaled breath. For rapid analysis and identification of VOC 
addtds, we additionally turned to direct-infusion nanoelectrospmy 
FT-Iffi-MS analysis. This muoscale sampling to:bnique matcbcxl 
the samples sizes of the mi.:roreactor, and the u1tra-high resolution 
FT-Iffi-MS enables simultaneous analysis of the ketone and aIde-
byde addu:ts, while avoiding analytical interference from the capture 
Thi5 journal is ~ The Royal Society of Chemistry 2011 
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A Novel Method for Preconcentration and Analysis of Trace 
Volatile Carbonyl Compounds 
Mingxiao Lia, Souvik Biswasb, Michael H. Nantzb, 
Richard M. Higashib,c, Xiao-An Fu*a 
Departments of 'Chemical Engineering and 2Chemistry, 3Center for Regulatory and 
Environmental Analytical Metabolomics (CREAM), and 4 James Graham Brown 
Cancer Center, University of Louisville, Louisville, Kentucky 40292 
ABSTRACT: This paper demonstrates a novel preconcentration approach for 
quantitative analysis of trace volatile ketones and aldehydes in air and in human 
breath. The approach is based on the fabricated microreactor chips on a silicon wafer. 
The microreactors have thousands of micropillars in the microfluidic channel for 
uniformly distributing gaseous sample flowing through the microreactors. The 
surfaces of the micropillars are functionalized with a quaternary ammonium 
aminooxy 2-(aminooxy)ethyl-N,N ,N-trimethylammonium iodide (ATM) synthesized 
in-house for trapping trace ketones and aldehydes by means of an oximation reaction. 
The ATM adduct and unreacted ATM can be easily eluted from the microreactor with 
less than 40 microliter of methanol and directly analyzed by nanospray Fourier 
transform-ion cyclotron resonance (FT-ICR) mass spectrometry (MS). Ketones and 
aldehydes in a concentration of 1 ppbv can be detected. The microreactor approach is 
suitable for quantitative analysis of ketones and aldehydes in exhaled breath. 
KEYWORDS: Preconcentration, Microreactor, Breath Analysis, Ketones, Aldehydes 
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Chapter 21 
Highly Specific, NIR Fluorescent Contrast Agent 
with Emission Controlled by Gold Nanoparticle 
Jianting Wang, Martin O'Toole, Archna Massey, Souvik Biswas, Michael Nantz, 
Samuel Achilefu, and Kyung A. Kang 
Abstract Nanoparticles are currently being intensively studied for in vivo molecular 
imaging because of their unique and beneficial properties. Among these particles, 
some metal particles possess strong surface plasmon fields that can effectively alter 
fluorescence. Using this fluorescence alteration, an NIR fluorophore based, nano-
sized contrast agent for breast cancer diagnosis is being developed. The fluorophore is 
conjugated to gold nanoparticles (GNP) via a short spacer whose length was specially 
adjusted to have the strong plasmon field to quench the fluorescence. The spacer also 
has a special molecular sequence that can be cleaved by an enzyme secreted by 
targeted cancer cells. Normally, the entity does not fluoresce. If it is delivered to the 
cancer site, the short spacer would be cleaved by the enzyme secreted by the cancer 
cell at which point the fluorescence would be restored. This entity can incorporate 
a cancer targeting molecule for a cancer specific delivery. The entity specifically 
targets cancer cells and fluoresce only when the spacer is cleaved by a specific 
cancer secreting biomolecule, providing dual specificity for cancer diagnosis. In the 
future, this entity will be combined with cancer drugs for seamless detection and 
personalized therapy. 
21.1 Introduction 
Fluorescence contrast agents have been extensively used in clinical diagnosis. Natu-
rally, the agents providing high specificity are highly desirable for molecular imag-
ing. Recently, nanoparticles have been intensively studied as candidates for image 
contrast agents and drug delivery because their small size allows interactions with 
Jianling Wang, Martin O'Toole, and Kyung A. Knng 
Department of Chemical Engineering, University of Louisville, Louisville, KY 40292, USA 
e--mail: kyung.kang@louisville.edu 
Archna Massey, Souvik Biswas, and Michael Nantz 
Department of Chemistry. University of Louisville, Louisville, KY 40292, USA 
Samuel Achilefu 
Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA 
Ie. LaManna et ai. (eels.), Ox)gmr Transport to TISsue XXXII, Advances in Experimental 149 
Medicine and Biology 701,00110.10071978-1-4419-7756-4_21, 
e Springer Science+Business Media, lLC 2011 
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1338 Taney Avenue, Apt 302 
Frederick, MD, 21702 
Nanotherapeutics; developing multifunctional nanoparticle-based platforms for drug 
delivery and bio-imaging 
Non-viral gene delivery; designing synthetic nano-vectors (e.g., Iiposomes and 
nanoparticles) for gene transfer 
Organic synthesis; developing targeted delivery systems for therapeutic agents and 




Preparation and characterization of cationic aminooxy-functionalized F~04 nanoparticles 
Synthesis, characterization, formulation and application of novel magnetic lipid particles 
for in vitro transfections 
Development of alternating magnetic field-induced heat shock protein (hsp) promoted 
gene delivery systems 
Design, formulation and optimization of cationic oxime ether lipids for gene transfer 
application 
Alternating Magnetic Field (AMF)-Triggered Drug Delivery 
Preparation, characterization and formulation of magnetic nano-carriers for doxorubicin 
Demonstration of in vitro AMF-triggered drug release and cell death 
Presently working on 3-D organo-mimic of human tumor model to substantiate the 
principles listed above 
Organic Synthesis 
Design and characterization of oxime ether conjugates of the anti-cancer drug 
doxorubicin 
Synthesis and characterization of novel cationic oxime ether lipids for targeted gene 
delivery 
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Synthesis and characterization of novel aminooxy-based reagents for various bio-medical 
applications 
Solid phase and solution phase syntheses of peptide-fluorophore conjugates (e.g., cypate) 
Synthesis of a panel of hydroxyethyl-based cationic lipids for use in microchip breath 
analyzer 
2005-2006 (Post M.8c. research; advisor: Prof. A. N. Maitra, University of Delhi, India) 
Formulation of highly stable water dispersed silver nanoparticles as an antimicrobial 
agent 
Glucose sensing ability of entrapped glucose oxidase in hollow gold nanoparticles 
KEY SKILLS 
Synthesis and Formulation 
Expertise in designing drug and gene delivery systems and synthesizing drug conjugates 
using "click" chemistry 
Expertise in surface functionalization and surface conjugation of nanopaparticles for 
biomedical applications 
Proficient at formulation of drug and gene delivery systems (e.g., liposomes, lipoplexes, 
and magnetoplexes) 
AMF-triggered Drug Delivery 
Experience with operating an alternating magnetic field generator for magnetic 
hyperthermia-induced drug delivery 
Molecular Biology 
Experience with drug release studies in cancer cells; evaluation of cytotoxicity using 
multiple assays 
Operation of fluorescence microscopy (AMG EVOS microscope) 
Extensive experience with non-viral methods of mammalian cell transfection; including 
the use of nanoparticles, magnetofection, cationic lipids, and polymers 
Familiar with different transfection assay systems (luciferase and GFP vector) 
EDUCATION 
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Thesis Advisor: Professor Michael H. Nantz 
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B.sc., Chemistry (with Honors), 2002 
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top three students in the M.Sc. Chemistry program at the University of Delhi) 
191 
PATENT and PUBLICATIONS 
Patent 
1. Nantz, M. H. and Biswas, S. Nanoparticles for Drug Delivery. PCTlUS20 1 0/53235 , 
Filed October 19, 2010. Patent pending (priority: Provisional Application 611252,934, 
Filed October 19,2009). 
Peer Reviewed Publications 
I. Biswas, S.; Gordon, L. E.; Clark, G. J.; Nantz, M. H. Click Assembly of Magnetic 
Nanovectors for Gene Delivery. Biomaterials 2011, 32, 2683-2688. 
2. Biswas, S.; Huang, X.; Badger, W. R.; Nantz, M. H. Nucleophilic Cationization 
Reagents. Tetrahedron Letters 2010, 51, 1727-1729. 
3. Biswas, S.; Knipp, R. J; Gordon, L. E.; Nandula, S. R; Gorr, S.-U; Clark, G. J.; Nantz, M. 
H. Hydrophobic Oxime Ethers: A Versatile Class of pDNA and siRNA Transfection 
Lipids. ChemMedChem 2011, 6, 2063-2069. 
4. Fu, X-A; Li, M; Biswas, S; Nantz, M. H.; Higashi, R. A. A Novel Preconcentration 
Approach for Analysis of Ketones and Aldehydes in Breath. Analyst 2011, 136,4662-
4666. 
5. Li, M; Biswas, S; Nantz, M. H.; Higashi, R. A.; Fu, X-A. A Novel Method for Detection 
of Ultra Trace Ketones and Aldehydes. Analytical Chemistry 2011, In Press. 
6. Biswas, S.; Gordon, L. E.; Clark, G. J.; Nantz, M. H. Externally Directed AMF-triggered 
Release of Doxorubicin from Magnetic Carriers. Nano Letters 2011, manuscript in 
preparation. 
7. Biswas, S.; Knipp, R. J.; Nantz. M. H. Smart Inorganic Nanoparticles for Doxorubicin 
Delivery. 2011, manuscript in preparation. 
Conference Proceedings and Presentations 
1. Biswas S.; Gordon, L. E.; Clark, G. J.; Nantz, M. H. Externally directed AMF-triggered 
release of doxorubicin from magnetic carriers. Poster no. 28; presented at the 7th 
Kentucky Innovation and Entrepreneurship Conference and 16th Kentucky EPSCoR 
Conference, Louisville, KY; May 26,2011. 
2. Biswas S.; Gordon, L. E.; Deb, B.; Mattingly, S. J.; Massey, A. P.; Clark, G. J.; Nantz, 
M. H. Magnetic Lipid Particles (MLPs): A New Class of Iron Oxide Nanoparticles for 
Gene Transfer. Poster no. 10; presented at the Inaugural Conference of the American 
Society for Nanomedicine, Potomac, MD; October 22-25,2009. 
3. Biswas S.; Gordon, L. E.; Deb, B.; Mattingly, S. J.; Massey, A.P.; Clark, G. J.; Nantz, M. 
H. Magnetic Lipid Particles (MLPs): A New Class of Iron Oxide Nanoparticles for Gene 
Transfer. Poster 18; presented at the 11th Annual IMD3 Symposium, Louisville, KY; 
March 10, 2009. 
TEACHNING EXPERENCE 
Invited lecturer for graduate level Advanced Organic Chemistry 679, Modem Methods of 
Organic Synthesis (University of Louisville, Spring 2011) 
Invited lecturer for undergraduate organic chemistry 341 and 342 (University of 
Louisville) 
Organic Chemistry Recitation: Graduate Teaching assistant (GTA) for Organic chemistry 
341 and 342 (fall 2007-summer 2008, Department of Chemistry, University of 
Louisville) 
Organic Chemistry Laboratory: GT A for Organic chemistry lab 344 (2007 spring and 
summer, Department of Chemistry, University of Louisville) 
192 
INSTRUMENTATION 
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